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A B S T R A C T
Background
Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment
with an antiviral agent is uncertain. This review was first published in 2001 and most recently updated in 2015. Since a significant benefit of
corticosteroids for the early management of Bell's palsy has been demonstrated, the main focus of this update, as in the previous version,
was to determine the effect of adding antivirals to corticosteroid treatment. We undertook this update to integrate additional evidence
and to better assess the robustness of findings, taking risk of bias fully into account.
Objectives
To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell's palsy.
Search methods
We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS in July 2019. We reviewed the
bibliographies of the identified trials and contacted trial authors to identify additional published or unpublished data. We searched clinical
trials registries for ongoing studies.
Selection criteria
We considered randomised controlled trials (RCTs) or quasi-RCTs of antivirals with and without corticosteroids versus control therapies
for the treatment of Bell's palsy. We excluded trials that followed-up participants for less than three months.
Data collection and analysis
We independently assessed trials for relevance, eligibility, and risk of bias, using standard Cochrane procedures. We performed sensitivity
analyses excluding trials at high or unclear risk of bias in at least five domains, and reported these data as the primary analyses.
Main results
Fourteen trials, including 2488 participants, met the inclusion criteria. Most were small, and most were at high or unclear risk of bias in
multiple domains. We included four new studies at this update.
Incomplete recovery
A combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in people with Bell's palsy
compared to corticosteroids alone (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.38 to 1.74; 3 trials, N = 766; random-effects; low-
certainty evidence). We excluded 10 trials that were at high or unclear risk of bias in several domains from this analysis and limited all
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analyses to studies at lower risk of bias. Recovery rates were better in participants receiving corticosteroids alone than antivirals alone
(RR 2.69, 95% CI 0.73 to 10.01; 2 trials, N = 667; random-effects), but the result was imprecise and allowed for the possibility of no effect.
The rate of incomplete recovery was lower with antivirals plus corticosteroids than with placebo or no treatment (RR 0.56, 95% CI 0.42 to
0.76; 2 trials, N = 658; random-effects). Antivirals alone had no clear effect on incomplete recovery rates compared with placebo, but the
result was imprecise (RR 1.10, 95% CI 0.87 to 1.40; 2 trials, N = 658; fixed-effect). For people with severe Bell's palsy (House-Brackmann
score of 5 and 6, or equivalent on other scales), we found that the combination of antivirals and corticosteroids had no clear effect on
incomplete recovery at month six compared to corticosteroids alone, although the result was again imprecise (RR 0.82, 95% CI 0.57 to
1.17; 2 trials, N = 98; random-effects).
Motor synkinesis or crocodile tears
Antivirals plus corticosteroids reduced the proportion of participants who experienced these long-term sequelae from Bell's palsy com-
pared to placebo plus corticosteroids (RR 0.56, 95% CI 0.36 to 0.87; 2 trials, N = 469; fixed-effect; moderate-certainty evidence). Antivirals
plus corticosteroids reduced long-term sequelae compared to placebo but there was no clear difference in this outcome with antivirals
alone compared to placebo.
Adverse events
Adverse event data were available in four studies providing data on 1592 participants. None of the four comparisons showed clear dif-
ferences in adverse events between treatment and comparison arms (very low-certainty evidence); for the comparison of antivirals plus
corticosteroids and corticosteroids alone in studies at lower risk of bias, the RR was 1.17 (95% CI 0.81 to 1.69; 2 trials, N = 656; fixed-effect;
very low-certainty evidence).
Authors' conclusions
The combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in comparison to corticos-
teroids alone in Bell's palsy of various degrees of severity, or in people with severe Bell's palsy, but the results were very imprecise. Corti-
costeroids alone were probably more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo
or no treatment. There was no clear benefit from antivirals alone over placebo.
The combination of antivirals and corticosteroids probably reduced the late sequelae of Bell's palsy compared with corticosteroids alone.
Studies also showed fewer episodes of long-term sequelae in corticosteroid-treated participants than antiviral-treated participants.
We found no clear difference in adverse events from the use of antivirals compared with either placebo or corticosteroids, but the evidence
is too uncertain for us to draw conclusions.
An adequately powered RCT in people with Bell’s palsy that compares different antiviral agents may be indicated.
P L A I N   L A N G U A G E   S U M M A R Y
Antiviral treatment for Bell's palsy
Review question
We reviewed the evidence about the effect of antiviral therapy (drugs used specifically to treat viral infections), alone or in combination
with any other therapy, on Bell's palsy. Our focus in this updated review was combined therapy with antiviral drugs and corticosteroids
(which are drugs used to reduce inflammation) as there is already good evidence that corticosteroids can reduce rates of incomplete
recovery from Bell's palsy.
Background
Bell's palsy is a disease of the facial nerve that causes one side of the face to be paralysed. Some studies have suggested that it is caused
by the same viral infections that cause cold sores or shingles and investigated the effect of antiviral therapy. Earlier versions of this review
have found that antivirals alone are not helpful compared to a dummy pill, and are less effective than corticosteroids alone. However,
studies of antiviral treatment in combination with corticosteroids have conflicting results.
Study characteristics
We identified 14 trials, which included 2488 participants with mild, moderate, or severe one-sided Bell's palsy of unknown cause. Partici-
pants were aged from 14 to 84 years. The trials compared:
- antivirals plus corticosteroids to corticosteroids alone or in combination with placebo;
- antivirals alone or in combination with placebo to placebo or no treatment;
- antivirals alone or in combination with placebo to corticosteroid treatment alone or in combination with placebo; or
- antivirals plus corticosteroids to placebo or no treatment.
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For the majority of the studies, no information on funding was given. The remaining were mostly partly public funded, and one trial was
funded by a pharmaceutical company.
Eleven studies had high or uncertain risk of bias from various factors that can systematically affect trial results. We chose to base our
conclusions only on data from three studies at a lower risk of bias.
Key results and certainty of the evidence
The review showed that there may be no clear difference in rates of incomplete recovery from Bell's palsy after treatment with the combi-
nation of antivirals and corticosteroids, compared to corticosteroids alone. This finding was of low certainty and was based on data from
three trials involving 766 people with Bell's palsy of various degrees of severity. We excluded data from 10 trials with multiple potential
sources of bias. However, we can be moderately confident that the combined therapy reduced the number of people leS with long-term
effects of Bell's palsy (excessive tearing of the eyes or an abnormal facial movement) compared to corticosteroid treatment alone.
Data from two studies (98 participants) showed that in people with severe Bell's palsy (complete or almost complete facial paralysis),
combined antivirals and corticosteroids had no clear effect on recovery compared with corticosteroid treatment alone.
Corticosteroids alone were more effective than antivirals alone on rates of incomplete recovery (667 participants, 2 trials); antivirals and
corticosteroids combined were more effective than placebo or no treatment (658 participants, 2 trials); and there was no clear benefit
from antivirals alone over placebo (658 participants, 2 trials).
Although, based on data from two trials (656 participants), we found no clear difference in the occurrence of side effects between people
receiving both antivirals and corticosteroids, compared to those receiving corticosteroids alone, this evidence is too uncertain for us to
draw conclusions.
Large studies in people with Bell's palsy comparing additional antiviral agents may be indicated in the future.
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Summary of findings for the main comparison.   Antivirals plus corticosteroids compared to corticosteroids plus placebo or no treatment (AS versus
OS) for Bell's palsy (idiopathic facial paralysis)
Antivirals plus corticosteroids compared to corticosteroids plus placebo or no treatment (AS versus OS) for Bell's palsy (idiopathic facial paralysis)
Patient or population: Bell's palsy (idiopathic facial paralysis)
Setting: primary, secondary and tertiary care
Intervention: antivirals plus corticosteroids (AS)
Comparison: corticosteroids plus placebo or no treatment (OS)
Anticipated absolute effects* (95% CI)Outcomes Relative ef-
fect
(95% CI) Corticos-
teroids plus
placebo or
no treatment
(OS)
Antivirals plus
corticosteroids
(AS)
Difference with AS
Certainty of
the evidence
(GRADE)
What happens
Study populationIncomplete recovery at end of
study
№ of participants: 766
(3 RCTs)
Follow-up: 3 to 12 months
RR 0.81
(0.38 to 1.74)
172 per 1000 140 per 1000
(65 to 300)
33 fewer per 1000
(107 fewer to 128
more)
⊕⊕⊝⊝
Lowa,b
There may be little or no difference be-
tween AS and OS in the proportion of
participants with incomplete recovery
at the end of the studies.
Study populationMotor synkinesis or crocodile
tears
№ of participants: 469
(2 RCTs)
Follow-up: 3 to 12 months
RR 0.56
(0.36 to 0.87)
194 per 1000 109 per 1000
(70 to 169)
85 fewer per 1000
(124 fewer to 25 few-
er per 1000)
⊕⊕⊕⊝
Moderatec
AS probably reduces the proportion of
participants with motor synkinesis or
crocodile tears at 3 to 12 months com-
pared to OS.
Study populationAdverse events
№ of participants: 656
(2 RCTs)
Follow-up: 3 to 12 months
RR
1.17 (0.81 to
1.68) 136 per 1000 160 per 1000
(110 to 229)
24 more per 1000 (26
fewer to 93 more)
⊕⊝⊝⊝
Very lowd,e
It is uncertain whether the number of
people who experience adverse events
is different with AS than OS.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
AS: antivirals plus corticosteroids; CI: confidence interval; OS: corticosteroids plus placebo or no treatment; RR: risk ratio
GRADE Working Group grades of evidence
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High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded the certainty of evidence once due to differing results of the included studies (inconsistency). As our primary analysis we reported the results of a sensitivity
analysis excluding 10 of 13 trials which were at high or unclear risk of bias in several domains. The effect estimate from the full data set was RR 0.54, 95% CI 0.38 to 0.77; 13 trials,
N = 1729 , but there were very serious study limitations in the full data set, in addition to heterogeneity.
bWe downgraded the certainty of the body of evidence once because the RR had wide CIs that included the possibility of a very little effect and a large effect (imprecision).
cWe downgraded the certainty of evidence for this outcome for publication bias, as only two studies in this comparison reported this outcome.
dWe downgraded the certainty of the body of evidence for this outcome once for publication bias as only 4 of the 13 studies reported adverse events.
eWe downgraded the certainty of the body of evidence twice for imprecision as the CIs were wide and encompassed the possibility of an effect in either direction.
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B A C K G R O U N D
Description of the condition
Bell's palsy is an acute, generally unilateral paralysis or weakness of
facial musculature consistent with peripheral facial nerve dysfunc-
tion, of no detectable cause (Niparko 1993). Additional symptoms
frequently include pain around or behind the ear on the affected
side, sometimes extending into the occipital or cervical regions. Im-
paired tolerance to ordinary levels of noise and disturbed sense of
taste on the affected side may also be present (Burgess 1984).
Epidemiological studies have reported an annual incidence of 23
to 25 per 100,000 per year, but a recent study using a general prac-
tice database suggests it may be even higher, at 37 per 100,000 per
year (Victor 1994; Martyn 1997; Morales 2013). The condition affects
men and women more or less equally, and was once thought to
be most common in the 30- to 45-year age group (Peitersen 1982;
Katusic 1986; Yanagihara 1988; Bateman 1992; Brandenberg 1993;
Peitersen 2002). However, a recent primary care database study
suggests a second peak in the over-70s (Morales 2013). Bell's palsy
presents disproportionately amongst pregnant women and people
who have diabetes, influenza, a cold, or some other upper respira-
tory ailment. On average, a British general practitioner will see one
person who has developed the condition every 12 to 18 months.
Both sides of the face are affected equally often (Prescott 1988).
The aetiology of Bell's palsy is still debated. A viral infection, vas-
cular ischaemia, autoimmune inflammatory disorders, and hered-
ity have been proposed as underlying causes (Adour 1982; Burgess
1984; Lorber 1996; Lackner 2010). A viral aetiology has gained pop-
ularity since the isolation of herpes simplex virus type 1 genome
from the saliva and facial nerve endoneurial fluid of people with
this condition (Murakami 1996; Lackner 2010). On the whole, the
prognosis is favourable, though a significant proportion of people
who are leS untreated have residual symptoms. One of the largest
series of people with Bell's palsy, which included people receiving
no treatment, showed that 85% of people began to recover with-
in three weeks after onset (Peitersen 1982). Partial recovery usual-
ly occurred within three to six months for the remaining 15%. The
same series showed that normal facial expression reappeared in
71% of cases, 13% had insignificant sequelae (long-term after ef-
fects), and the final 16% had permanently diminished function with
aberrant innervation (expressed as motor synkinesis or autonomic
dysfunction), and postparalytic spasms.
Description of the intervention
The treatment of Bell's palsy was highly controversial until 2008,
at which time corticosteroids alone were shown to be effective
in treating the condition (Madhok 2016). Previous Cochrane Re-
views on the treatment of Bell's palsy examined the effective-
ness of oral prednisolone and aciclovir or valaciclovir (Allen 2004;
Lockhart 2009; Gagyor 2015c). Several studies excluded from the
analysis in these reviews either failed to randomise participants
or, when correctly randomised, results were erroneously interpret-
ed in a favourable light (May 1976; Wolf 1978). High-dose corticos-
teroid therapy has several potential side effects, including peptic
ulceration, hypertension, and confusional states. Antiviral therapy
was considered expensive, and treatment was reserved for circum-
stances in which a clear benefit appeared likely. Previous recom-
mendations suggested that antivirals needed to be started within
48 hours, although a study of viral replication in participants with
Bell's palsy suggests that the window might be extended (Abiko
2002).
How the intervention might work
Bell's palsy is associated with an inflammation of the facial nerve.
Since herpes simplex virus has been detected in cerebrospinal fluid
of affected patients, antiviral treatment was tested in trials aiming
to eradicate the virus (Murakami 1996).
Why it is important to do this review
Corticosteroids are widely used in the treatment of idiopathic fa-
cial paralysis (Bell's palsy), but the effectiveness of additional treat-
ment with an antiviral agent is uncertain. The 2009 update of this
Cochrane Review included large-scale randomised controlled tri-
als (RCTs) of antivirals and corticosteroids that had been published
in the years before the review. The authors stated that, compared
to placebo, antivirals did not contribute to a significant improve-
ment in the rate or extent of recovery of trial participants (Lockhart
2009), but that when added to corticosteroids, the rate of recov-
ery was slightly better than corticosteroids alone or corticosteroids
with placebo. This result was confirmed in the last update which
included three additional trials (Gagyor 2015c). The review authors
requested withdrawal of an update of the review published earlier
that year (Gagyor 2015b), as it also included a fourth trial (Abdel-
ghany 2013), which has since been withdrawn. We requested with-
drawal of that version of the review and republished our analyses.
Since a significant benefit of corticosteroids for the early manage-
ment of Bell's palsy has been previously demonstrated (Lockhart
2009; Madhok 2016), the main focus of this update, as in the previ-
ous version, was to determine the effect of the combination of an-
tivirals and corticosteroids versus corticosteroids alone or in com-
bination with placebo. The current review updates these findings
with additional studies and involves a reanalysis of the results us-
ing sensitivity analyses, excluding studies at high or unclear risk of
bias in at least five categories.
O B J E C T I V E S
To assess the effects of antiviral treatments alone or in combination
with any other therapy for Bell's palsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We searched for all randomised controlled trials (RCTs) or qua-
si-RCTs (which are trials that employ alternate or other systemat-
ic allocation) involving an antiviral (aciclovir, valaciclovir, or famci-
clovir) alone or in combination with any other therapy in the treat-
ment of Bell's palsy, reported in any language. The duration of stud-
ies included in this review ranges from three to 12 months; the min-
imum study duration was three months. Unlike the previous ver-
sion of the review we did not exclude studies at high risk of bias,
but conducted sensitivity analyses to determine their effect on the
outcome. Studies were eligible for the review regardless of publi-
cation status.
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Types of participants
We considered all trials where participants had a diagnosis of uni-
lateral facial paralysis of unknown cause and satisfied the trial au-
thors' requirements for eligibility and inclusion.
Types of interventions
We considered all trials of treatment with any oral antiviral licensed
for the treatment of herpes simplex infection in immunocompe-
tent participants. Antivirals include aciclovir; valaciclovir, which is
a prodrug of aciclovir; and famciclovir, which is a prodrug of pen-
ciclovir. We considered trials where participants received antiviral
therapy alone or in combination with any other treatment versus
placebo or any other treatment.
Types of outcome measures
We have described changes to outcome measures in this and pre-
vious versions of the review in Differences between protocol and
review.
Primary outcomes• Incomplete recovery of facial function at the end of study, mea-
sured using a validated rating scale
Secondary outcomes• Motor synkinesis or crocodile tears at the end of the study• Adverse events• Incomplete recovery at month six in severe cases
Some trials have reported other symptoms (pain, discomfort, and
embarrassment) as outcomes, but we did not consider them in this
review.
Search methods for identification of studies
Electronic searches
The Cochrane Neuromuscular Information Specialist searched the
following databases.
• The Cochrane Neuromuscular Specialised Register via the
Cochrane Register of Studies (CRS-Web) (31 July 2019; Appendix
1).• The Cochrane Central Register of Controlled Trials (CENTRAL)
via the Cochrane Register of Studies (CRS-Web) (31 July 2019;
Appendix 2).• MEDLINE (1946 to 30 July 2019; Appendix 3).• Embase (1974 to 29 July 2019; Appendix 4).• LILACS (1982 to 30 July 2019).
We searched for registered trials on:
• ClinicalTrials.gov (June 2019; www.clinicaltrials.gov; Appendix
6);• Australian New Zealand Clinical Trials Registry (June 2019;
www.anzctr.org.au);• World Health Organization International Clinical Trials Registry
Platform (June 2019; www.who.int/ictrp/en; Appendix 7).
Searching other resources
We also reviewed the bibliographies of the identified trials and con-
tacted trial authors and known experts in the field and relevant
drug companies to identify additional published or unpublished
data.
Data collection and analysis
We conducted the following four comparisons.
• Antiviral treatment in combination with corticosteroids versus
corticosteroid treatment alone or in combination with placebo• Antiviral treatment alone or in combination with placebo versus
placebo or no treatment• Antiviral treatment alone or in combination with placebo versus
corticosteroid treatment alone or in combination with placebo• Antiviral treatment in combination with corticosteroids versus
placebo or no treatment
Selection of studies
Two review authors working in pairs (IG and VM) scrutinised titles
and abstracts for potentially eligible studies. Both review authors
independently assessed each full-text paper for eligibility and se-
lected studies for inclusion. We had no disagreements about inclu-
sion. FS supervised all steps of the study selection.
Data extraction and management
Two review authors (IG and VM) extracted data onto a data extrac-
tion form and double-checked data extraction in pairs. They agreed
data input into the Cochrane authoring and statistical software, Re-
view Manager 5 (RevMan 2014). They discussed any disagreements
with a third review author (FD) to reach a resolution. We arranged
translation of papers where necessary.
Assessment of risk of bias in included studies
Two review authors (IG and VM) independently assessed the risk
of bias in included studies using the 'Risk of bias' methodology de-
scribed in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). FD reviewed the 'Risk of bias' assessments
to achieve agreement where there were differences. The review au-
thors considered methods of randomisation and allocation con-
cealment, blinding (of treatment administrator and participants,
and outcome assessors), selective outcome reporting (for example,
failure to report adverse events), and incomplete outcome data (i.e.
dropouts). We assessed each trial as at high, low, or unclear risk of
bias for each of these criteria.
Measures of treatment e9ect
All our outcomes were dichotomous. We analysed the data as risk
ratios (RRs) with corresponding 95% confidence intervals (CIs).
When comparing studies that used different symptom scales to
assess the primary outcome, incomplete recovery, we used the
House-Brackmann scale when available (House 1985), as this was
used most widely and could be compared with other scales. The
main outcome in all trials was complete recovery. For this review,
the review authors calculated the number of participants with in-
complete recovery by subtracting the number of participants with
complete recovery from the number of participants in the reference
group.
Antiviral treatment for Bell's palsy (idiopathic facial paralysis) (Review)
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When assessing adverse events, we used the number of partici-
pants affected as opposed to the number of events, to facilitate da-
ta comparison.
'Summary of findings' table
We created a 'Summary of findings' table for the comparison 'an-
tivirals plus corticosteroids versus corticosteroids plus placebo or
no treatment'. We presented this single comparison because corti-
costeroids are known to be effective, and the main focus of this up-
date, as for the previous version, was to determine whether adding
antivirals to corticosteroid treatment provides additional benefit.
We presented the following outcomes.
• Incomplete recovery at the end of the study (House-Brackmann
scale; House 1985)• Motor synkinesis or crocodile tears at the end of the study
(House-Brackmann scale)• Adverse events
We used the five GRADE considerations (risk of bias, inconsistency
of effect, imprecision, indirectness, and publication bias) to assess
the certainty of a body of evidence (studies that contribute data
for the prespecified outcomes) using the GRADEpro GDT 2015 com-
puter programme. We started with a judgement for RCTs at high
certainty and downgraded the evidence one level to moderate cer-
tainty, two levels to low certainty, and three levels to very low cer-
tainty according to the GRADE criteria. For any single consideration,
we downgraded the evidence once, if present, to a serious degree
and twice, if very serious. We employed methods and recommen-
dations described in Section 8.5 and Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
using GRADEpro software (GRADEpro GDT 2015). We justified all de-
cisions to downgrade or upgrade the certainty of evidence using
footnotes.
Unit of analysis issues
Each of the included studies carried out randomisation at the par-
ticipant level. Twelve trials used a simple parallel-group design
(Adour 1996; Li 1997; De Diego 1998; Hato 2007; Kawaguchi 2007;
Minnerop 2008; Vázquez 2008; Yeo 2008; Shahidullah 2011; Lee
2013; Khajeh 2015; Khedr 2016). Two trials used a factorial design
(Sullivan 2007; Engström 2008).
For studies with a factorial design, we aggregated groups according
to whether or not antivirals were administered. We have described
details in the Results.
Dealing with missing data
We contacted authors of three studies for additional data that were
required for analysis but which were not provided in their papers
(Minnerop 2008; Khajeh 2015; Khedr 2016), but only one respond-
ed with unpublished data (Minnerop 2008). We used the Kawaguchi
2007 data provided in previous versions of this review.
Assessment of heterogeneity
We used the I2 statistic to assess heterogeneity among the included
studies in each analysis. If we found substantial unexplained het-
erogeneity, we reported it and explored possible causes according
to the subgroup analyses.
Assessment of reporting biases
We produced a funnel plot to assess the likelihood of publication
and small-study bias as there were sufficient studies in our antivi-
rals plus corticosteroids versus corticosteroids plus placebo or no
treatment incomplete recovery analysis (Egger 1997).
Data synthesis
We calculated a treatment effect using the Mantel-Haenszel
method (Egger 2007). We used the random-effects model where we
found marked heterogeneity (I2 = 40% or greater) between studies.
If we had found little or no heterogeneity, we would have used a
fixed-effect analysis.
Subgroup analysis and investigation of heterogeneity
We expected heterogeneity in the effect estimates for incomplete
recovery due to the following factors and conducted a subgroup
analysis when the published studies or study authors provided suf-
ficient data.
• The investigated corticosteroid was prednisolone; however, dif-
ferent antivirals were used. Most trials combined prednisolone
with aciclovir, but some trials used valaciclovir or famciclovir.
We performed subgroup analysis for each antiviral to assess po-
tential differences in participant response to the three different
antiviral medications.• We planned to investigate whether time to treatment had an in-
fluence on incomplete recovery, when data were available.
Some studies included participants with a broad range of symptom
severity, while others included severe cases only. We performed
an additional antivirals plus corticosteroids versus corticosteroids
plus placebo or no treatment analysis for incomplete recovery of
people with severe Bell's palsy at baseline, using data from four
trials. Severe Bell's palsy was defined as severe-to-complete facial
paralysis, graded as equal to or greater than V in the House-Brack-
mann grading system (House 1985; Table 1), equal to or less than 20
in the Sunnybrook score (Ross 1996; Table 2), and equal to or less
than 20 in the Yanagihara score (Yanagihara 2003; Table 3). We did
not perform an analysis of non-severe cases.
Sensitivity analysis
We performed sensitivity analyses to investigate:
• the effects of bias by excluding trials that had a high or unclear
risk of bias in at least five categories;• whether our conclusions were altered when we excluded stud-
ies with a follow-up of less than six months; and• the robustness of the results by changing between a fixed-effect
model and a random-effects model.
R E S U L T S
Description of studies
Results of the search
The previous version of the review included 10 studies and we
added four studies that we had previously excluded. We found
222 records through database searching for this update and none
through other sources. After removal of duplicates, we screened
183 records and excluded 149 records based on their titles and ab-
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stracts. After checking the full texts, we excluded 20 full-text arti-
cles. We included 14 studies (which were reported in 14 separate
publications) in the review, and included all 14 in quantitative syn-
thesis (meta-analysis). (Figure 1). We did not find any ongoing stud-
ies in the World Health Organization International Clinical Trials
Registry Platform (www.who.int/ictrp/en).
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Figure 1.   Study flow diagram.
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Included studies
We added four RCTs with 208 participants to the previous version
of this review, which had 10 trials and 2280 participants. The new-
ly added trials were Minnerop 2008, Shahidullah 2011, Khajeh 2015
and Khedr 2016. Two trials have been published since previous
searches in the 2015 review (Khajeh 2015; Khedr 2016). Although
we excluded Minnerop 2008 and Shahidullah 2011 from the pre-
vious update (Gagyor 2015c), due to their high or unclear risk of
bias, we included both studies in the current analysis, and assessed
the 'Risk of bias' and the certainty of evidence, as recommended
by the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Diagnostic criteria
Thirteen studies gave adequate information (Li 1997; De Diego
1998; Hato 2007; Kawaguchi 2007; Sullivan 2007; Engström 2008;
Minnerop 2008; Vázquez 2008; Yeo 2008; Shahidullah 2011; Lee
2013; Khajeh 2015; Khedr 2016). All studies explicitly mentioned
a diagnosis of Bell's palsy and stated that they had considered
and excluded other causes of facial palsy. Three trials, Hato 2007,
Kawaguchi 2007 and Shahidullah 2011, retrospectively excluded
participants on the basis of positive serology for herpes simplex or
varicella zoster virus, or due to other exclusion criteria. Lee 2013
excluded participants who did not fulfil inclusion criteria, without
specifying the reasons. Two studies mentioned referral to special-
ists for diagnostic confirmation (Sullivan 2007; Engström 2008).
Khedr 2016 excluded people with mild to moderate Bell's palsy. The
remaining study, Adour 1996, stated that participants were diag-
nosed with Bell's palsy, but did not give any further information.
Outcome criteria
All studies used referenced facial function scoring systems to grade
recovery from facial paralysis. Adour 1996 and De Diego 1998 used
the Facial Paralysis Recovery Profile (Adour 1971), and Adour 1996
also used the Facial Paralysis Recovery Index (Adour 1974). Ha-
to 2007 and Kawaguchi 2007 used the Yanagihara scoring system
(Yanagihara 2003), which has a validated system for conversion to
the House-Brackmann scale (House 1985). Li 1997, Sullivan 2007,
Engström 2008, Yeo 2008, Minnerop 2008, Shahidullah 2011, Lee
2013, Khajeh 2015, and Khedr 2016 presented results using the
House-Brackmann scale. Engström 2008 and Khedr 2016 supple-
mented this with use of the Sunnybrook scale to minimise the ef-
fects of inter-rater variability (Ross 1996). Vázquez 2008 used a fa-
cial grading scale related to the Sunnybrook scale (Ross 1996).
The 14 studies in the current review included 2488 participants (see
Characteristics of included studies).
Adour 1996 was a single-centre study that recruited 119 partici-
pants, of whom 99 were included in the published analysis. The
study was double-blind and placebo-controlled. Participants were
recruited within three days or less of onset of paralysis and received
either aciclovir and prednisolone or placebo and prednisolone. The
study duration was four months; participants were reviewed at two
weeks, two months, and four months. The Facial Paralysis Recov-
ery Index was used to measure facial function; the primary trial out-
come was incomplete recovery defined by a Facial Paralysis Recov-
ery Index of 7 or less.
De Diego 1998 recruited 113 participants and included 101 partic-
ipants in the final analysis. Participants were randomly assigned
to treatment. Baseline assessment was carried out within 48 hours
of the onset of symptoms. Participants received either aciclovir for
10 days or prednisolone for 16 days (reducing dose). Reviews were
scheduled for one, three, six, and 12 weeks after initial contact, with
further contact if persistent incomplete recovery was noted. The
primary study outcome was recovery, as defined by a House-Brack-
mann scale of 2 or less (House 1985), or a Facial Paralysis Recovery
Profile (Adour 1974) of 8 or more. The report did not give the final
length of follow-up, but stated that it continued "until complete re-
covery or stabilization of the paralysis".
Li 1997 recruited 51 participants within four days of onset of Bell's
palsy. Participants were randomly assigned into two groups, who
received either aciclovir plus prednisolone or prednisolone. Good
recovery was defined as a House-Brackmann scale of 1 or 2 at
month six (House 1985). Li 1997 reported outcomes for 46 partici-
pants; five were lost to follow-up.
Hato 2007 randomised 296 participants within seven days after on-
set, using sealed envelopes into two treatment groups: valaciclovir
with prednisolone or placebo with prednisolone. The final analysis
included 221 participants. Administrators and those assessing re-
covery status were not blinded to the treatment allocation, but par-
ticipants were blinded to the treatment received. Disease severity
was assessed using the Yanagihara 40-point scoring system (Yanag-
ihara 2003); participants were considered to have completely re-
covered if they attained a score greater than 36. Participants were
assessed at onset and monthly thereafter for either six months or
until completely recovered, if recovery occurred before six months.
Kawaguchi 2007 recruited 150 participants who were treated
within seven days of onset and randomised using sealed en-
velopes into two treatment groups: valaciclovir plus prednisolone
or prednisolone alone. There was inadequate clinician blinding.
Kawaguchi and colleagues provided unpublished data on incom-
plete recovery for a previous update. Participants were assessed at
one, two, three, four, five, and six months after inclusion using the
Yanagihara scale (Yanagihara 2003). We could not contact the au-
thors to obtain data for subsequent updates, but we included the
data published in the earlier version of the review.
Sullivan 2007 recruited 551 participants, who were treated within
72 hours of onset. Participants were randomised by a dedicated re-
mote telephone computerised mechanism, in a two-stage process,
into four treatment groups: aciclovir with prednisolone, aciclovir
with placebo, placebo with prednisolone, or double placebo, in a
factorial design. The trial was blinded for administrator, partici-
pant, and assessment of recovery status until the end of follow-up.
Participants were assessed at onset, after three months and, if still
unwell at three months, and after nine months. Recovery status
was measured using the House-Brackmann scale (House 1985),
with complete recovery defined as House-Brackmann Grade 1. Da-
ta analysis included an assessment of treatment interaction. Sulli-
van 2007 reported final outcomes on 496 completed participants
at three months and nine months, in treatment groups that were
aggregated, as for Engström 2008.
Engström 2008 recruited 829 participants, who were treated with-
in 72 hours of onset and randomised in a two-stage process by a
computerised mechanism into four treatment groups: valaciclovir
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with prednisolone, valaciclovir with placebo, placebo with pred-
nisolone, or double placebo, in a factorial design. The trial was dou-
ble-blind (administrator and participant) for assessment of recov-
ery status until the end of follow-up. Participants were assessed at
onset, after two weeks (11 to 17 days), and after one, two, three,
six, and 12 months. The disease status was measured using the
House-Brackmann grading system (House 1985), and the Sunny-
brook scale (Ross 1996). Complete recovery status was defined by
a Sunnybrook score of 100 and House-Brackmann Grade 1. Time
to recovery was estimated. Data analysis included an assessment
of treatment interaction. For this review, we analysed the recovery
rates 12 months after the onset of facial palsy, and defined com-
plete recovery as a House-Brackmann Grade 1.
Minnerop 2008 included 167 participants with facial paralysis, aged
18 years and older, who were treated within five days after onset.
Participants were randomised in two parallel groups: those admit-
ted on even dates were assigned to prednisone (10 days), partici-
pants admitted on odd dates were randomised to prednisone and
famciclovir (7 days). Treatment was administered unblinded. Of the
167 participants randomised, 50 were lost to follow-up, and only
117 participants were analysed. Although the main outcome was
defined as complete recovery at three months, only 47 were as-
sessed as planned. The rest of the study participants returned be-
fore month three or after month 12. Data from these 47 participants
were sent by the trial author. The assessors in the trial used the
House-Brackman scale or a similar score and complete recovery
was not defined.
Vázquez 2008 included 42 participants and reported outcomes at
six and 12 months using the Sunnybrook Facial Grading System
(Ross 1996). Scores greater than 90 were defined as a satisfactory
recovery. Participants in the intervention group were treated with
prednisone and valaciclovir and in the control group with pred-
nisone and placebo. The main study outcome was the proportion
of participants with total recovery at six months' follow-up in each
group, and average time to recovery in each group.
Yeo 2008 recruited 91 participants who were randomised to re-
ceive either aciclovir and prednisolone or prednisolone alone. Par-
ticipants also received physical therapy and plasma volume ex-
panders as adjuncts. The trial was double-blind and investigators
followed up participants for six months, or until complete recovery.
Recovery was assessed using the House-Brackmann scale and was
defined as a House-Brackmann scale of 2 or less (House 1985).
Shahidullah 2011 carried out a randomised, controlled, open-label
study with clinic patients aged 15 years and older who had unilater-
al facial paralysis of unknown cause. Participants were quasi-ran-
domised, based on odd and even numbers, and were treated either
with famiciclovir (5 days) plus prednisolone (7 days), or with pred-
nisolone alone (7 days). Of the 107 participants recruited, 30 had
exclusion criteria and nine were lost to follow-up, so data from 68
patients were analysed. Participants were assessed at baseline us-
ing the House-Brackman scale and were followed up one week, one
month and three months after inclusion. Complete recovery was
defined as House-Brackman scale Grade 1.
Lee 2013 was a RCT in participants with severe-to-complete Bell's
palsy, which used the House-Brackmann scale for assessment
(House 1985). The trial included 201 participants with a score
of 5 or more. After randomisation into two groups, participants
received either famciclovir plus prednisolone together, or pred-
nisolone alone. Recovery was designated as a score of 1 or 2 on the
House-Brackmann scale at month six.
Khajeh 2015 randomised 43 children, aged from 2 to 18 years,
with unilateral Bell's palsy in two parallel groups. Participants were
treated within three days after onset of Bell's palsy with either pred-
nisolone and aciclovir or prednisolone only for seven days. The ran-
domisation method was not stated. This open-label trial did not
use a placebo. The trial assessed the severity of Bell's palsy by the
House-Brackman scale. Complete recovery was defined as Grade 1.
Participants were assessed at onset, four weeks, and three months
after onset.
Khedr 2016 recruited 65 people with Bell's palsy, between 18 and
60 years old, and excluded 15 people with mild and moderate Bell's
palsy. The 50 included participants were randomised in two groups
using serially-numbered, opaque, closed envelopes. Participants
began treatment with prednisolone and aciclovir or prednisolone
alone within three days after onset and treatment lasted seven
days for prednisolone, and five days for aciclovir. The trial authors
stated that the study was blinded, but did not use a placebo. Out-
come data were assessed at baseline, two weeks, two months,
and three months after inclusion, using the House-Brackman scale.
Complete recovery was defined as Grades 1 and 2.
Excluded studies
The authors of the previous version of this review excluded Antunes
2000 because of incomplete data in 44 participants. Despite our at-
tempts to contact the authors, there was still insufficient informa-
tion for the data to be usefully included in analyses.
The authors of a previous version of this review reassessed the
inclusion of the two studies that were awaiting assessment (de
Aquino 2001; Roy 2005). Dr D Allen, the author of a previous version
of this review, attempted to contact the lead author of de Aquino
2001 for clarification of the data, but this was not forthcoming.
We therefore excluded this trial because of a lack of adequate in-
formation. The latter study recruited 82 participants, of whom 18
dropped out, and compared aciclovir plus methylprednisolone to
methylprednisolone alone, reporting no benefit from the addition
of aciclovir. The authors did not provide outcome data in the ab-
stract, which appeared in a journal supplement, and according to
the search strategies employed, the trial has not been published to
date as a full paper. We excluded this trial due to a lack of adequate
information.
A further study was classified as awaiting assessment in the previ-
ous version of this review (Inanli 2001). This paper was included in
another systematic review and a meta-analysis (de Almeida 2009;
Goudakos 2009). We excluded it from the current review because
we could not find it in print or electronic form. See Characteristics
of excluded studies.
Overall, we excluded six studies for not being RCTs (Ibarrondo 1999;
Axelsson 2003; Hato 2003; Hultcrantz 2005; Ahangar 2006; Kang
2015); three for having a very short follow-up (Zhou 1999; Chen
2005; Ferreira 2016); three because reports provided insufficient in-
formation to assess the methods or outcomes (Antunes 2000; de
Aquino 2001; Roy 2005); three due to scarcity of data and the wrong
study population (only an abstract was available and 15 of 45 par-
ticipants had Ramsay Hunt syndrome, and were given intravenous
therapy) (Ramos Macias 1992), another trial had a lack of outcome
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data, as described above (Roy 2005), one paper was not available
(Inanli 2001); and we excluded one paper from the previous update,
as the paper was found to be plagiarised and has since been retract-
ed (Abdelghany 2013).
Ongoing studies
We identified two trial reports in children with Bell's palsy in a
search of ClinicalTrials.gov and the Australian New Zealand Clinical
Trials Registry just prior to completion of the review (www.clinical-
trials.gov; www.who.int/ictrp/en). Both studies are still recruiting.
See Ongoing studies.
Studies awaiting classification
We found one trial in children and adults with Bell's palsy in a search
of the World Health Organization International Clinical Trials Reg-
istry Platform (www.who.int/ictrp/en), which was characterised as
completed. We contacted the authors for more information about
the current status of the trial but did not receive a reply. See Stud-
ies awaiting classification.
Risk of bias in included studies
We have summarised 'Risk of bias' assessments in Figure 2.
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Figure 2.   A summary of review authors' 'Risk of bias' assessments for included studies. Red = high risk of bias;
yellow = unclear risk of bias; green = low risk of bias.
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Figure 2.   (Continued)
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Allocation
Three studies were at low risk of selection bias, being adequate-
ly randomised, with allocation concealment (Adour 1996; Sullivan
2007; Engström 2008).
Two other studies were at low risk of bias from the method of ran-
domisation, but at high or unclear risk of bias from inadequate allo-
cation concealment (Kawaguchi 2007; Lee 2013). Lee 2013 reported
a later onset of the treatment in the combination treatment group,
without significance. The trial used a simple randomisation gener-
ated by Microsoft Excel to intervention and control but the authors
did not provide information on allocation concealment (Lee 2013).
Kawaguchi 2007 did not conceal allocation, the allocation envelope
contained the name of the treatment group, Although this trial re-
ported a significant difference between mean ages of the treatment
groups, further analysis of the age distribution using the Chi2 test
revealed no significant difference.
In seven studies, the risk of bias from the method of randomisa-
tion and allocation concealment were unclear (Li 1997; De Diego
1998; Hato 2007; Vázquez 2008; Yeo 2008; Khajeh 2015; Khedr 2016).
De Diego 1998, Vázquez 2008, Yeo 2008 and Khajeh 2015 did not
describe the randomisation method or measures to conceal allo-
cation. Li 1997 used codes, but provided little information on ran-
domisation. Khedr 2016 and Hato 2007 reported the use of en-
velopes, and in Khedr 2016 these were serially-numbered, opaque
and closed, but the reports provided insufficient detail for a clear
judgement.
Minnerop 2008 and Shahidullah 2011 were at high risk of bias
for randomisation as they used even and odd days or numbers
to randomise the participants. In Minnerop 2008, there were 25%
more participants in the prednisolone group than in the combina-
tion treatment group. Shahidullah 2011 included more participants
with severe Bell's palsy in the combination treatment group than
in the prednisolone alone group. Minnerop 2008 was not blinded
and unlikely to have concealed allocation. Allocation concealment
in Shahidullah 2011 was unclear.
Blinding
Adour 1996, Li 1997, Sullivan 2007 and Engström 2008 were de-
scribed as double-blind and placebo-controlled trials and we as-
sessed them at low risk of performance bias. All used placebo
and described methods for adequate blinding of the trial drug. De
Diego 1998, Hato 2007, Kawaguchi 2007, Minnerop 2008, Shahidul-
lah 2011, Lee 2013, and Khajeh 2015 were open-label and we as-
sessed them at high risk of bias. Vázquez 2008, Yeo 2008 and Khe-
dr 2016 stated that the study was double-blind; however, the text
does not describe this and the trials were not placebo-controlled,
so we assessed their risk of bias for blinding (performance bias) as
unclear.
For blinding of the outcome assessor, we assessed two trials at low
risk of bias (Sullivan 2007; Engström 2008). The remaining studies
were at high or unclear risk of bias.
Incomplete outcome data
All studies except Yeo 2008 and Khajeh 2015 reported frequencies,
and often reasons, for failure to complete follow-up. We assessed
five trials at low risk for incomplete outcome data (Kawaguchi 2007;
Sullivan 2007; Vázquez 2008; Engström 2008; Khedr 2016). These tri-
als reported a dropout rate of less than 10%.
We assessed De Diego 1998 at unclear risk of bias due to a dropout
rate of 10%. Two trials also reported a dropout rate of less than 10%
but reasons for drop out were not given in the paper (Yeo 2008; Li
1997). We assessed these studies at unclear risk of bias for this rea-
son, as for Khajeh 2015. The remaining five studies were at high risk
of bias in this category: Lee 2013 reported a dropout rate of 13.1%,
Adour 1996 17%, Hato 2007 25%, and Shahidullah 2011 27%. Min-
nerop 2008 reported a loss to follow-up rate of 30%, but for the cur-
rent review, data from only 30% of the study population (partici-
pants assessed between 3 and 12 months) fulfilled the inclusion cri-
teria of this review. None of the studies assessed as high and un-
clear risk of bias used the intention-to-treat approach to control
this.
Selective reporting
All studies except Adour 1996 and Kawaguchi 2007 reported all in-
tended primary outcomes. Adour 1996 failed to report on audiom-
etry and stapedial reflex testing. Engström 2008 reported all pri-
mary outcomes; secondary outcomes were reported in later pub-
lished papers (Axelsson 2012; Berg 2012). Minnerop 2008 reported
the main outcome for all participants independently from the time
of the assessment, and published data were insufficient to differen-
tiate between those who were eligible to be included in this review
(participants who were assessed within the defined time period of
3 to 12 months) and those who were not. Khajeh 2015 did not report
baseline data.
Seven studies did not report adverse events (Li 1997; De Diego 1998;
Kawaguchi 2007; Yeo 2008; Lee 2013; Khajeh 2015; Khedr 2016).
Other potential sources of bias
Statistical analysis
Twelve of the 14 studies analysed gave adequate detail; they clearly
stated and then used appropriate statistical tests. We only scored
Hato 2007 'unclear' in this category, as the authors did not ade-
quately describe the tests used. We scored Shahidullah 2011 'high'
for this and in addition due to baseline differences between groups
at inclusion.
Baseline dierences between groups
Eight of the 14 trials were adequate in this category. De Diego 1998
found a significant difference in rates of hypertension between the
two groups, but further analysis revealed that there was no signif-
icant difference in trial outcomes as a result. Kawaguchi 2007 re-
ported a significant difference between mean ages of the treatment
groups, but further analysis of the age distribution using the Chi2
test revealed no significant difference. Lee 2013 reported a later on-
set of treatment in the combination treatment group, without sig-
nificance but it was of unclear risk for excluding of two participants
with adverse events in the steroid group (not clearly specified) from
the analysis.
We assessed two trials at unclear risk in this category: Khajeh 2015
reported only age and sex at baseline and there was a difference be-
tween the groups, and in Minnerop 2008 there were 25% more par-
ticipants in the prednisolone group than in the combination treat-
ment group. We scored Shahidullah 2011 as high risk of bias; it in-
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cluded more participants with severe Bell's palsy in the combina-
tion group than in the prednisolone alone group.
E9ects of interventions
See: Summary of findings for the main comparison Antivirals
plus corticosteroids compared to corticosteroids plus placebo or
no treatment (AS versus OS) for Bell's palsy (idiopathic facial paral-
ysis)
As the included trials reported different intervals and lengths of
follow-up, we performed the analyses on data reported at three
months (De Diego 1998; Khajeh 2015; Khedr 2016; Shahidullah
2011), six months (Li 1997; Hato 2007; Kawaguchi 2007; Vázquez
2008; Yeo 2008; Lee 2013), nine months (Sullivan 2007), or 12
months (Engström 2008), after the start of treatment.
For the subgroup analysis of incomplete recovery in participants
with severe Bell's palsy at onset, we either extracted data at month
six, in Hato 2007 and Lee 2013, or imputed data to month six, in
Sullivan 2007 and Engström 2008.
Throughout this section of the review, we utilised the following no-
tation.
• AO: antiviral treatment alone or in combination with placebo
• AS: antiviral treatment in combination with corticosteroids• OO: placebo or no treatment• OS: corticosteroid treatment alone or in combination with
placebo
Antivirals plus corticosteroids versus corticosteroids plus
placebo or no treatment (AS versus OS)
This comparison included 13 studies with 1729 participants (Adour
1996; Li 1997; Hato 2007; Kawaguchi 2007; Sullivan 2007; Engström
2008; Minnerop 2008; Vázquez 2008; Yeo 2008; Shahidullah 2011;
Lee 2013; Khajeh 2015; Khedr 2016). We restricted our main analy-
ses to studies at low or unclear risk of bias in fewer than five do-
mains. See Summary of findings for the main comparison.
Incomplete recovery
Three studies comparing AS and OS were at high or unclear risk of
bias in fewer than five categories (Adour 1996; Sullivan 2007; En-
gström 2008). Pooled data from these three studies found no clear
difference between AS and OS (risk ratio (RR) 0.81, 95% confidence
interval (CI) 0.38 to 1.74; 3 trials, N = 766; random-effects; low-cer-
tainty evidence). The result showed substantial heterogeneity (Chi2
= 5.30, df = 2 (P = 0.07); I2 = 62%) and was imprecise, with a CI that
encompassed effects in either direction (Analysis 1.1; Figure 3).
 
Figure 3.   Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no
treatment (AS versus OS): sensitivity analysis based on risk of bias (excluding studies at high or unclear risk of bias
in fewer than five domains), outcome: 1.1 Incomplete recovery at end of study.
 
When the analysis used all the available evidence, the rate of in-
complete recovery was lower after AS than OS (RR 0.59, 95% CI 0.47
to 0.70; 13 trials, N = 1729; fixed-effect; very low-certainty evidence).
Heterogeneity was substantial (Chi2 = 20.03, df = 12 (P = 0.07), I2 =
40%); we used the random-effects model to adjust for this (RR 0.54,
95% CI 0.38 to 0.77; Analysis 1.2; Figure 4).
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Figure 4.   Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no
treatment (AS versus OS): trials at lower risk of bias, outcome: 1.2 Incomplete recovery at end of study (full data
set).
 
We also investigated the effect of AS versus OS by performing a
sensitivity analysis (on the whole data set) to investigate the effect
of removing studies with a follow-up of less than six months (i.e.
Adour 1996; Shahidullah 2011; Khajeh 2015; Khedr 2016). We found
that this did not substantially alter the findings (RR 0.65, 95% CI 0.45
to 0.94; Chi2 = 12.75, df = 8 (P = 0.12); I2 = 37%; 9 trials, N = 1469;
random-effects).
Subgroup analysis: e9ect of di9erent antiviral agents
In our analysis of trials at lower risk of bias, we presented data for
this outcome subgrouped by antiviral agent: aciclovir (Adour 1996;
Sullivan 2007), or valaciclovir (Engström 2008). There were too few
trials for reliable subgroup analysis (Analysis 1.1)
We performed this subgroup analysis on the full data set: aci-
clovir (Adour 1996; Li 1997; Sullivan 2007; Yeo 2008; Khajeh 2015;
Khedr 2016); famciclovir (Minnerop 2008; Shahidullah 2011; Lee
2013); and valaciclovir (Hato 2007; Engström 2008; Vázquez 2008;
Kawaguchi 2007). Trials that studied the effects of aciclovir (RR
0.43, 95% CI 0.22 to 0.83; 6 trials, N = 580) and famiciclovir (RR 0.48,
95% CI 0.22 to 1.06; 3 trials, N = 321) showed large effects in favour
of AS over OS. Yet, the valaciclovir subgroup showed a smaller ef-
fect in favour of AS over OS and more imprecision (RR 0.79, 95% CI
0.57 to 1.08; 4 trials, N = 828; Analysis 1.2). The statistical test for
subgroup differences did not support a subgroup effect: Chi2 = 3.44,
df = 2 (P = 0.18); I2 = 41.9%.
Additional analysis: severe cases
For this comparison, we extracted data from four studies (Hato
2007; Sullivan 2007; Engström 2008; Lee 2013).
We restricted our main analysis to two studies at lower risk of bias
(Sullivan 2007; Engström 2008). The proportion of participants with
incomplete recovery showed no clear difference in the AS group
versus the OS group among people with severe Bell's palsy (RR 0.82,
95% CI 0.57 to 1.17; 2 studies, N = 98; Chi2 = 0.72, df = 1 (P = 0.40); I2
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= 0%; random-effects; Analysis 1.3; Figure 5). The result was impre-
cise but without statistical heterogeneity.
 
Figure 5.   Forest plot of comparison: 3 Antivirals plus corticosteroids versus placebo, outcome: 3.1 Incomplete
recovery at end of study.
 
When the analysis used all the available evidence (i.e. also includ-
ing Hato 2007 and Lee 2013), the proportion of participants with
incomplete recovery was slightly lower in the AS group versus the
OS group in people with severe Bell's palsy. The result was also im-
precise (RR 0.64, 95% CI 0.41 to 0.99; 4 trials, N = 478; random-ef-
fects). Heterogeneity was moderate (Chi2 = 5.2, P = 0.16, I2 = 42%)
(see Analysis 1.4).
Motor synkinesis or crocodile tears
Adour 1996 and Engström 2008 provided data on motor synkinesis
or crocodile tears, assessed at the end of the study. The analysis in-
cluded 469 participants and showed that fewer participants expe-
rienced these long-term sequelae after AS than after OS (RR 0.56,
95% CI 0.36 to 0.87; 2 trials, N = 469; Chi2 = 0.25, df = 1 (P = 0.62);
I2 = 0%; fixed-effect; moderate certainty-evidence; Analysis 1.5). As
both trials were of low risk of bias in most domains, we did not per-
form a sensitivity analysis.
Adverse events
Four trials comparing AS versus OS reported on adverse events, re-
porting data from 945 participants (Hato 2007; Sullivan 2007; En-
gström 2008; Shahidullah 2011).
The analysis including only the studies at a low risk of bias (i.e.
Sullivan 2007 and Engström 2008), showed no clear difference be-
tween AS and OS in the number of participants experiencing ad-
verse events (RR 1.17, 95% CI 0.81 to 1.69; 2 trials, N = 656; Chi2 =
0.26, df = 1 (P = 0.61); I2 = 0%; fixed-effect; Analysis 1.6).
The result using all the available evidence was similar to evidence
from studies at low risk of bias, with no clear difference in the num-
ber of participants with adverse events between the AS and the OS
group (RR 1.16, 95% CI 0.83 to 1.63; 4 trials, N = 945; Chi2 = 0.39, df =
3 (P = 0.94); I2 = 0%; fixed-effect; very low-certainty evidence; Analy-
sis 1.7).
Antivirals versus corticosteroids (AO versus OS)
This comparison contained three studies (De Diego 1998; Sullivan
2007; Engström 2008).
Incomplete recovery
All three studies (768 participants) provided data for our primary
outcome, incomplete recovery at the end of the study.
Our primary analysis, which excluded De Diego 1998 due to a high
or unclear risk of bias in five domains, produced a RR of 2.69, 95%
CI 0.73 to 10.01; 2 studies, N = 667; Chi2 = 7.41, df = 1 (P = 0.006); I2
= 87%; random-effects; Analysis 2.1). The result favoured corticos-
teroids; however heterogeneity was substantial and the CI did not
exclude the possibility of no difference between the groups.
Analysis of all three trials (i.e. including De Diego 1998), also found a
greater proportion of participants treated with AO had incomplete
recovery than those treated with OS. Initial calculations using the
fixed-effect model showed a RR of 1.96, 95% CI 1.48 to 2.59; 3 trials,
N = 768, but with a high degree of heterogeneity (Chi2 = 8.78, df = 2
(P = 0.01); I2 = 77%). We repeated the analysis using the random-ef-
fects model to adjust for this, and the RR was 2.82, 95% CI 1.09 to
7.32; Analysis 2.2).
Motor synkinesis or crocodile tears
De Diego 1998 and Engström 2008 provided data for the outcome,
motor synkinesis or crocodile tears at the end of the study.
After removing De Diego 1998 (unclear or high risk of bias in 5 do-
mains) the results from Engström 2008 showed that more partici-
pants had sequelae with AO than OS (RR 1.70, 95% CI 1.15 to 2.50;
1 trial, N = 371; Analysis 2.3).
Analysis of the full data set including 472 participants also found
more participants had sequelae after AO than OS (RR 1.52, 95% CI
1.08 to 2.12; 2 trials, N = 472; Chi2 = 1.50, (P = 0.22); I2 = 33%; fixed-
effect; Analysis 2.4).
Adverse events
Two trials reported this outcome (Sullivan 2007; Engström 2008).
Fewer participants experienced adverse events in the AO group
than the OS group (RR 0.85, 95% CI 0.57 to 1.28; 2 trials, N = 658;
Chi2 = 0.05, df = 1 (P = 0.82); I2 = 0%; fixed-effect; very low-certainty
evidence; Analysis 2.5), but the CIs included the possibility of the
opposite effect (Sullivan 2007; Engström 2008). Due to a low risk of
bias in most domains of both trials, we did not perform a sensitivity
analysis.
Antivirals plus corticosteroids versus placebo (AS versus OO)
This comparison contained two studies and outcome data on 658
participants (Sullivan 2007; Engström 2008).
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Incomplete recovery
There was a large effect on the rates of incomplete recovery at the
end of the study that favoured AS compared with OO (RR 0.56, 95%
CI 0.42 to 0.76; 2 trials, N = 658; Chi2 = 0.14, df = 1 (P = 0.71); I2 =
0%; random-effects; Analysis 3.1; Figure 5). We did not perform a
sensitivity analysis in this data set since the risk of bias was low in
both included studies.
Motor synkinesis or crocodile tears
One trial reported the effect of the intervention on motor synkinesis
or crocodile tears (Engström 2008), and showed a reduction in the
AS versus the OO group, with a RR of 0.37, 95% CI 0.23 to 0.59; 1 trial,
N = 372; random-effects; Analysis 3.2).
Adverse events
Using the data from both trials, there was little or no difference be-
tween treatment with AS and OO in the proportion of participants
with adverse events (RR 1.14, 95% CI 0.79 to 1.65; 2 trials, N = 649,
Chi2 = 0.13, df = 1 (P = 0.72); I2 = 0%; fixed-effect; Analysis 3.3).
Antivirals versus placebo (AO versus OO)
Two studies investigated this comparison (Sullivan 2007; Engström
2008). We did not perform a sensitivity analysis in this comparison,
as both trials were at lower risk of bias.
Incomplete recovery
Two trials compared antivirals versus placebo without any compli-
cating additional treatment (Sullivan 2007; Engström 2008). AO had
no clear effect on the proportion of participants with incomplete
recovery (RR 1.10, 95% CI 0.87 to 1.40; 2 trials, N = 658). There was
imprecision and the heterogeneity was moderate (Chi2 = 1.63, P =
0.20, I2 = 39%; fixed-effect; Analysis 4.1).
Motor synkinesis or crocodile tears
Only Engström 2008 reported results for this outcome (RR 1.04, 95%
CI 0.75 to 1.43; 1 trial, N = 373; random-effects; Analysis 4.2.
Adverse events
The proportion of participants who had adverse events was similar
in the AO and OO groups, but the result was imprecise (RR 0.83, 95%
CI 0.56 to 1.24; 2 trials, N = 651; Chi2 = 0.33, df = 1 (P = 0.57); I2 = 0%;
fixed-effect; Analysis 4.3).
Funnel plot
We included a funnel plot, which shows some asymmetry of the
distribution of the studies. This suggests small-study effects and
may reflect differences in methodological quality or publication
bias (Figure 6).
 
Figure 6.   Funnel plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no
treatment (AS versus OS): trials at lower risk of bias, outcome: 1.2 Incomplete recovery at end of study (full data
set).
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D I S C U S S I O N
Summary of main results
We identified 14 studies of antivirals in Bell's palsy that provided
data for analyses. They included 2488 participants. We were un-
able to draw any conclusions from analysis of the 14 studies, as the
certainty of evidence was very low, primarily due to study limita-
tions and inconsistency. When we limited our analysis to data from
three studies at lower risk of bias, results indicated that the combi-
nation of antivirals and corticosteroids may have little or no effect
on rates of incomplete recovery compared to corticosteroids alone
(see Summary of findings for the main comparison). There was
no clear difference in rates of incomplete recovery among partici-
pants with severe Bell's palsy in the group treated with the combi-
nation of antiviral treatment and corticosteroids versus those who
received corticosteroid treatment alone or in combination with
placebo, in contrast with results based on the full data set from peo-
ple with severe disease, which found a slightly lower rate of incom-
plete recovery with antiviral treatment in combination with corti-
costeroids compared to corticosteroid treatment alone or in com-
bination with placebo.
The rate of incomplete recovery was higher in participants receiv-
ing antivirals alone or in combination with placebo than in those
who received corticosteroids alone or in combination with place-
bo. The rate of incomplete recovery was lower with the combina-
tion of antivirals and corticosteroids than with placebo or no treat-
ment, but antivirals alone or in combination with placebo had no
clear effect compared with placebo or no treatment. For these out-
comes, we analysed data from two or three trials only. Apart from
the comparison of antivirals in combination with corticosteroids
versus placebo or no treatment, the trials showed a moderate to
high degree of heterogeneity and wide confidence intervals (CIs).
Three studies evaluated sequelae (long-term effects) of Bell's palsy,
crocodile tears and motor synkinesis, at the end of the study. They
found that there were probably fewer instances of long-term seque-
lae in people who received the combination of antivirals and corti-
costeroids compared with the group who received corticosteroids
alone or in combination with placebo (Engström 2008). These se-
quelae were also less frequent in those who were treated with an-
tivirals alone or in combination with placebo compared with corti-
costeroids alone or in combination with placebo (Adour 1996; En-
gström 2008), and in those treated with the combination of antivi-
rals and corticosteroids compared with placebo or no treatment
(Engström 2008).
Data did not show clear differences in the adverse events in any of
the comparisons.
Overall completeness and applicability of evidence
Although the number of included studies and participants have in-
creased since the last update of this review, the additional stud-
ies did not contribute to the certainty of the evidence. The exter-
nal validity of most evidence was low, which limited interpretation
of the results. The heterogeneity found in analyses may be due to
clinical variation, for example in participant characteristics, age,
disease severity at baseline, delay in receiving treatment, or dif-
ferent type of antiviral agent used, and also different time points
of measurements of the outcome. Heterogeneity was exacerbated
in many studies by keeping the inclusion criteria fairly broad; this
maximised data inclusion, and therefore power, but results must
be interpreted with this in mind. Furthermore, the different defini-
tions of severe Bell’s palsy in the trials, depending on the symptom
scores should also be considered a potential source of heterogene-
ity. Other limitations are the high or unclear risk of bias in several
domains and the small size of the majority of included trials. Giv-
en the likely overall small or absent effect of antivirals, it is unlikely
that different antiviral compounds will have a significant effect on
incomplete recovery at the end of the study, despite the difference
in bioavailability (Sullivan 2007).
We found differences in severity at recruitment: Li 1997, Hato 2007,
Vázquez 2008, Yeo 2008, Lee 2013 and Khedr 2016 included a more
severe spectrum of palsy. Hato 2007 and Engström 2008 stratified
participants by severity of disease status at onset. Hato 2007 found
that in cases of complete or severe palsy, the recovery rate for the
combination treatment was greater than for participants treated
only with OS. Lee 2013 included only severe cases and found a
higher rate of recovery in the group receiving a combination treat-
ment using famciclovir. Khedr 2016 excluded patients with mild
to moderate palsy and showed benefit from a combination treat-
ment. In contrast, Engström 2008 could not confirm these find-
ings in treatment of participants with severe Bell's palsy, whereas
in Sullivan 2007, combined treatment with antivirals and corticos-
teroids showed increased rates of incomplete recovery over corti-
costeroids alone. The analysis of participants with severe Bell's pal-
sy showed no clear effect of the combination treatment.
We found variation in the clinical endpoints chosen as defining re-
covery: Sullivan 2007, Engström 2008, Shahidullah 2011 and Khajeh
2015 used House-Brackmann scale Grade 1 (House 1985), while Li
1997, Yeo 2008, Lee 2013 and Khedr 2016 used House-Brackmann
scale Grade 1 and 2. Minnerop 2008 did not define recovery. The
other studies used a variety of different scales that show more or
less equivalence to these. We have provided details of the symp-
toms scales and comparisons, where available (Table 1, Table 2, Ta-
ble 3).
Equally, heterogeneity could be due to methodological or design
differences in the studies, such as the method of randomisation,
use of blinding, choice of outcome measures and recovery cut-oK
points, or trial duration. In particular, Li 1997, De Diego 1998, Ha-
to 2007, Kawaguchi 2007, Minnerop 2008, Shahidullah 2011, Kha-
jeh 2015 and Khedr 2016 had methodological weaknesses, either
in baseline group assessment or in completeness of follow-up, and
adequacy of blinding. Any of these factors could result in bias and
introduce inaccuracy. Sensitivity analysis of trials not meeting cur-
rent best standards (that is, high or unclear risk of bias) changed the
findings from a large effect into little or no effect, especially in the
primary outcome of our main analysis. We concluded that it was
the studies at higher risk of bias that suggested benefit from the
combination treatment. Our sensitivity analysis of trials with a six-
month endpoint corresponded with this finding and also showed a
change in the result compared to the whole group analysis.
Subgroup analyses on the whole data set revealed some differ-
ences between the different antivirals used. We showed a benefit
for the combination treatment with aciclovir and famciclovir but
not for valaciclovir. This appears to be a subgroup effect but this
can also be explained by the heterogeneity of the trials. The statisti-
cal test for subgroup differences did not identify a significant differ-
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ence. An additional analysis among participants with severe Bell's
palsy, showed little or no effect of the combination treatment. Tak-
ing both into account, subgroup analyses and the analysis in peo-
ple with severe Bell's palsy were helpful in explaining the hetero-
geneity of the overall analysis.
From the data available for analysis of motor synkinesis or croc-
odile tears at the end of the study, the results favoured antiviral
treatment in combination with corticosteroids compared to cor-
ticosteroid treatment alone or in combination with placebo, and
also corticosteroid treatment alone or in combination with place-
bo compared to antiviral treatment alone or in combination with
placebo (Analysis 1.5; Analysis 2.3). In the analysis of the whole da-
ta set (3 studies with a total of 941 participants), the degree of clin-
ical heterogeneity (different clinical assessment scales used) and
methodological heterogeneity (different treatment regimens and
follow-up plans) limited interpretation of the data. There was no
clear difference between groups based on data from trials at a low-
er risk of bias, but the data were imprecise.
Adverse event data were available in four studies, giving compar-
ison data for 1592 participants, but the certainty of evidence was
very low; the CIs in the analyses were wide and encompassed the
possibility of an effect in either direction (Sullivan 2007; Hato 2007;
Engström 2008; Shahidullah 2011).
It was unclear whether time to treatment influenced recovery. Nei-
ther Kawaguchi 2007 nor Yeo 2008 found an association between
time to treatment and final recovery status, but most of the trials
did not provide data on this outcome.
The review included studies conducted in Asia, North and Middle
America, and Europe. It is possible that genetic differences in drug
metabolism or response or even different aetiological processes
may account for some of the observed variation in response.
The primary outcome result raises another important considera-
tion, namely health economic issues: a 10-day course of aciclovir
400 mg five times per day costs GBP 2.04 (USD 2.69, EUR 2.29). The
cost of valaciclovir is similar: 1000 mg three times per day for sev-
en days costs GBP 10.12 (USD 12.97, EUR 11.38); 2 g once daily for
seven days costs GBP 6.75 (USD 8.90, EUR 7.59), or 1000 mg once
daily for 5 days costs GBP 2.41 (USD 3.18, EUR 2.71). Famciclovir 250
mg three times per day for seven days and 250 mg three times per
day for five days is significantly more expensive and likely to cost
the same at GBP 155.32 (USD 204.90, EUR 174.69). A 10-day course
of prednisolone (2 25 mg tablets daily) costs GBP 26.79 (USD 35.34,
EUR 30.13), much less than for the antivirals. These cost data are
specific to the UK market (NHS Surrey Downs 2018), and costs vary
significantly in other countries (Hernández 2008).
Certainty of the evidence
The certainty of evidence in the current review does not allow ro-
bust conclusions regarding incomplete recovery for the compari-
son of antiviral treatment in combination with corticosteroids ver-
sus corticosteroid treatment alone or in combination with placebo
(Summary of findings for the main comparison). We downgraded
the certainty of evidence for the main comparison to low since the
risk ratio (RR) had a wide CI that included the possibility of very little
effect (imprecision) and for inconsistency of the results. This analy-
sis was performed after removal of studies at high or unclear risk of
bias and did not confirm the previously demonstrated effect Sum-
mary of findings for the main comparison. Some studies showed a
benefit and others a detrimental effect of AS in participants with
Bell's palsy. The funnel plot shows asymmetry of the distribution of
the studies, indicating the possibility of publication bias and small-
study effects (Figure 6).
The body of evidence identified for motor synkinesis and crocodile
tears was small because only two trials provided data and one of
them had a small sample size.
Very low-certainty evidence showed no differences in the occur-
rence of adverse events. We downgraded the body of evidence due
to publication bias, for imprecision, as the CIs were wide and en-
compassed the possibility of an effect in either direction, and be-
cause the proportion of participants lost to follow-up was large in
some of the included trials.
Potential biases in the review process
To help ensure that decisions about which studies to include in
this review were reproducible, two review authors repeated the re-
view process. Regarding application of the eligibility criteria and as-
sessing the relevance of studies, review authors were aware of the
names of the study authors, institutions, journal of publication, and
results. FS and FD were authors of the Sullivan 2007 study.
According to previous practice in this review, we excluded sever-
al studies and a published abstract for different reasons (Excluded
studies). As a result, there could be some risk of publication and se-
lective reporting bias due to data from some studies being unavail-
able.
At this update our main analyses excluded studies at high or un-
clear risk of bias in at least five domains. We listed this sensitivity
analysis in the methods in a previous version of this review, but did
not previously present it as the primary analysis. Even this restrict-
ed set of data included a trial at high risk of bias in two domains with
a large effect size, which if excluded from the analysis would move
the results of the efficacy analyses for antiviral treatment in combi-
nation with corticosteroids versus corticosteroid treatment alone
or in combination with placebo closer towards the null (Adour
1996). The results are highly sensitive to study inclusion and risk of
bias decisions, and true effects may be substantially different from
the estimates in the review. We used the Cochrane 'Risk of bias' tool
as currently implemented to assess bias in studies (Higgins 2011),
and checked and corrected previous judgements as appropriate. It
is probable that implementation of the new 'Risk of bias' tool will
again change estimates of effect (Higgins 2019). Future updates will
restrict the main analyses to studies at a low overall risk of bias
based on judgements in the new tool.
On the advice of the Cochrane Neuromuscular Statistical Editor, we
did not also perform a prespecified sensitivity analysis, excluding
studies with fewer than 200 participants, which had also been de-
scribed in the methods of a previous version of the review, as this
was considered too arbitrary a restriction.
Agreements and disagreements with other studies or
reviews
We found two systematic reviews, three meta-analyses and a net-
work meta-analysis comparing corticosteroids and antivirals for
the treatment of Bell's palsy (de Almeida 2009; Goudakos 2009;
Quant 2009; Numthavaj 2011; Dong 2015; Fu 2018). De Almeida and
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colleagues compared any corticosteroid treatment with antivirals
and included 18 trials in the meta-analysis. Some of the trials did
not meet the inclusion criteria for this review (i.e. for follow-up du-
ration of at least 3 months). De Almeida reported a benefit from cor-
ticosteroids for people with Bell's palsy and the probability of ad-
ditional benefit when corticosteroids were combined with antivi-
rals. A systematic review and meta-analysis by Goudakos and col-
leagues compared corticosteroids with corticosteroids plus antivi-
rals for the treatment of Bell's palsy. This review included only four
trials and omitted other important studies, for example Engström
2008, which is the largest trial conducted on this topic. Goudakos
did not find an additional benefit from combining corticosteroids
with antivirals. The meta-analyses by Numthavaj and colleagues
and Quant and colleagues included six trials for analysis, with a
great overlap (Quant 2009; Numthavaj 2011). In both papers the au-
thors reported higher rates of recovery when corticosteroids were
combined with antivirals compared to corticosteroids alone, but
the difference was small. Also Dong and colleagues recommended
the combination treatment of corticosteroids and antivirals, based
on the results of a meta-analysis with eight trials (Dong 2015). Fu
and colleagues conducted a network meta-analysis and included
data of 4623 participants from 23 studies. The analysis comprised
a large number of studies and included also data of a withdrawn
trial Abdelghany 2013. The authors concluded that the effect of the
combined treatment of antivirals and corticosteroids was signifi-
cantly better than antiviral or corticosteroid therapy alone with re-
gard to overall recovery in people with Bell's palsy (Fu 2018). How-
ever, none of the meta-analyses reported data from studies with a
low risk of bias separately, as the current meta-analysis does.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Among participants with Bell's palsy of various degrees of sever-
ity, combination therapy with antivirals and corticosteroids may
have little or no effect on rates of incomplete recovery in compari-
son to corticosteroids alone, and there may be no clear difference
with the combination therapy compared to corticosteroids alone
among people with severe Bell's palsy.
Corticosteroids alone were probably more effective than antivirals
alone with regard to recovery rates, and antivirals plus corticos-
teroids were more effective than placebo or no treatment. There
was no clear benefit from antivirals alone over placebo.
The combination of antivirals and corticosteroids probably reduce
the late sequelae of Bell's palsy compared with corticosteroids
alone. The studies also showed fewer episodes of long-term se-
quelae in corticosteroid-treated participants compared with antivi-
ral-treated participants.
We found no clear difference in adverse events from the use of an-
tivirals compared with either placebo or corticosteroids, but the ev-
idence was too uncertain for us to draw conclusions.
Implications for research
When we excluded small trials at high risk of bias from our analy-
ses, we did not find convincing evidence of an improvement in rates
of incomplete recovery in people with severe Bell's palsy follow-
ing combined treatment with antivirals and corticosteroids, com-
pared to corticosteroids alone. Although this evidence came from
less than one-third of the trials, they were those at low risk of bias,
and the evidence, while still of low certainty, may be more reliable
than the complete data set. A further large independent, well-con-
ducted study might help replicate and confirm these findings. Ad-
ditional work in this area could address the question of the best
treatment for mild to moderate and severe Bell's palsy raised by the
possible causes of heterogeneity in most of the comparisons in this
review. Depending upon the results of this analysis, an adequate-
ly powered randomised controlled trial (RCT) in people with Bell’s
palsy comparing additional antiviral agents or immune modulators
may be indicated.
More work is needed to assess the likelihood of long-term cosmetic
sequelae, which should be reported in all future trials. There is no
further need to conduct trials with a placebo group on this topic, as
a clear benefit from corticosteroid therapy is evident. Moreover, in
future studies, antivirals should be tested in combination with cor-
ticosteroids and not alone if an antiviral effect is expected. Future
studies should be done to assess the impact of the variables, such
as time from diagnosis until treatment, severity of palsy at baseline,
and age of participants at presentation on outcomes. Work assess-
ing a wider range of endpoints, such as quality of life and perceived
disability, should be undertaken with the goal of developing a bet-
ter understanding of Bell's palsy for the affected person.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by year of study]
 
Methods Randomised, placebo-controlled double-blind trial, two parallel groups
Participants The trial was conducted in primary care clinics and emergency departments in North America in 119
participants with confirmed facial paralysis. Data of 99 participants were published. Age range: > 18
years
The mean age was 41.9 (SD 14.1) years in the aciclovir plus prednisolone group (N = 53) and 44.6 (SD
15.1) years in the prednisolone plus placebo group (N = 46). In the combination treatment group 45%
were women, whereas the prednisolone group had 57% women.
Inclusion criteria
• Paralysis commenced ≤ 3 days before treatment• All participants over 18 years of age• Good physical health determined by history and physical exam• No contraindication for corticosteroid or aciclovir treatment• All women of childbearing age had a negative pregnancy test result
lack of clear definition of diagnostic criteria (possibly affects generalisability/validity)
Exclusion criteria
• Any other medication for idiopathic facial paralysis• Urea nitrogen or creatinine > 2x upper limit of normal• Liver transaminase > 3x upper limit of normal• Haemoglobin level < 100 g/L• Platelet count < 75,000/mm3 or neutrophil count < 1 x 10 to the 6/L
Loss to follow-up: 20 patients (group allocation unknown)
Interventions Aciclovir (2000 mg per day for 10 days) and prednisone (1 mg/kg for 5 days tapered to 10 mg/day for re-
maining 5 days) or placebo and prednisone (1 mg/kg for 5 days tapered to 10 mg/day for remaining 5
days)
Outcomes Primary outcome
• Recovery on facial paralysis recovery index, where incomplete recovery is a Facial Paralysis Recovery
Profile ≤ 7 (Adour 1974), at 4 months
Maximal stimulation test with or without electroneurography at follow-up at 2 weeks, 2, 3, and 4
months (if incomplete recovery) after paralysis onset
Adour 1996 
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Final outcomes reported at 3 months or when recovered or palsy stabilised (not more clearly defined)
Seconday outcomes
• Motor synkinesis• Adverse events
Funding Grants from Burroughs Welcome Company and the Community Service Program of Kaiser Foundation
Hospitals Inc. Elmore C. Wallace contributed additional funding
Conflicts of interest Information not given
Date conducted Information not given, presumably 1995
Notes Single-centre
The authors stated a dropout rate of 16.8%. The reason for dropout was documented for each partici-
pant, such as inability to keep appointments, low adherence to the treatment regimen, adverse events,
and moving from the area.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the bottles [of aciclovir and placebo], provided by Burroughs Well-
come, were randomised in groups of 10"
Allocation concealment
(selection bias)
Low risk Quote: "Each bottle...had a sealed identification label which was removed in-
tact and kept with the patient's record"
Blinding of participants? Low risk Quote: "eligible patients were given identical, unlabeled bottles of 100 cap-
sules that contained either placebo or aciclovir (Zovirax), 200 mg"
Comment: participants in each group received identical follow-up
Blinding of assessors? Low risk The study was reported as double-blind; the method reported was consistent
with being able to achieve this
Incomplete outcome da-
ta?
High risk The numbers of participants unable to complete the study was given. High
dropout rate reported: 16.8%. Not an intention-to-treat analysis
Selective outcome report-
ing?
High risk Primary outcomes of facial paralysis recovery profile and bilateral facial nerve
electrical testing reported, but no data given on audiometry with stapedial re-
flex testing; adverse events were not specified
Other sources of bias? Low risk No other risks of bias reported
Adour 1996  (Continued)
 
 
Methods Randomised, placebo-controlled, double-blind trial, two parallel groups
Participants This trial in the Second Teaching Hospital of the Ya'an Medical College, Shaanxi, China included 51 par-
ticipants, 5 of whom were lost to follow-up. Participants with other causes of facial palsy were exclud-
ed. The age range was 15 to 73 years. The mean age was 39.2 in the aciclovir plus prednisolone group
and 40.3 in the prednisolone group.
Inclusion criteria
Li 1997 
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• Acute Bell's palsy, 4 days before enrolment to study• No association with acute or chronic middle ear disease, cranial or otologic trauma, known central or
peripheral neurological disease, autoimmune disease and herpes zoster oticus
Exclusion criteria
• Contraindication to corticosteroid therapy• Peptic ulcer disease• Active tuberculosis• Pregnancy• Hypertension• Diabetes mellitus
Interventions Randomised to receive either aciclovir and prednisone or placebo and prednisone. Prednisone was ad-
ministered to both groups in a dose of 60 mg for 5 days then tapered in steps of 10 mg for a further 5
days. In the intervention group 800 mg aciclovir was given 5 times daily for 7 days. All participants re-
ceived artificial tears and ophthalmic ointments
Outcomes Primary outcome
• Recovery of facial motor function up to 6 months
House-Brackmann scale was used for assessment; recovery was taken as Grade 1 to 2
Follow-up weekly for the first month, then monthly until recovery
Final outcomes reported at 6 months, adverse events were not reported
Funding No information given
Conflicts of interest No information given
Date conducted January 1995 to June 1996
Notes Single-centre
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Simple randomisation by coding of treatment drugs; little information provid-
ed
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not clearly described
Blinding of participants? Low risk Blinding procedure described as coded tablets containing either aciclovir or
placebo
Blinding of assessors? Unclear risk Blinding procedure not clearly described
Incomplete outcome da-
ta?
Unclear risk Per protocol analysis, 5 participants were lost to follow-up. Unclear whether
intention-to-treat analysis was used
Selective outcome report-
ing?
Unclear risk Primary outcomes were reported, adverse events were not reported
Other sources of bias? Low risk Not identified
Li 1997  (Continued)
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Methods Randomised, controlled trial, two parallel groups
Participants The trials was carried out in Spain at the Department of Otorhinolaryngology, La Paz Hospital, Au-
tonomous University, Madrid, Spain. 113 participants with Bell's palsy were randomised, 101 were in-
cluded in published analysis. The mean age was 43 years (age range 14 to 85 years). 56 patients were
men (55.4%) and 45 were women (44.6%).
Inclusion criteria
• Diagnosis of idiopathic facial nerve paralysis and baseline assessment was carried out within 96 hours
Exclusion criteria
• Acute or chronic middle ear disease• Cranial or otologic trauma• Known central or peripheral neurologic disorders• Autoimmune diseases• Tumors• Herpes zoster oticus (Ramsay Hunt syndrome)
Patients must have no contraindications to corticosteroid or aciclovir therapy. These included peptic
ulcer, tuberculosis, moderate or severe diabetes, moderate or severe hypertension, glaucoma, mani-
fest cardiac disease, psychosis, renal or hepatic dysfunction, and pregnancy. To be considered as hav-
ing mild hypertension, patients must not have had blood pressure levels higher than 140/90 mm Hg
with diet or medical therapy.
Interventions Aciclovir (2400 mg/day for 10 days) (N (analysed) = 54) or prednisone (1 mg/kg for 10 days then tapered
to zero over the next 6 days) (N (analysed) = 47)
Outcomes Primary outcome
• Complete recovery using the House-Brackmann scale (≤ 2) and the Facial Paralysis Recovery Profile
(≥ 8)
Secondary outcomes
• Sequelae and synkinesis reported separately
Final outcomes reported at 4 months
Follow-up at 1, 3, 6, 12 weeks after first visit. Participants with incomplete recovery at 12 weeks were
followed up until recovery or stabilisation of paralysis
Funding Information not given
Conflicts of interest Information not given
Date conducted Between May 1994 and August 1995
Notes Single-centre
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "patients were randomly assigned". Randomisation method not de-
scribed
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Allocation concealment
(selection bias)
Unclear risk No clear information on concealment
Blinding of participants? High risk Presence of blinding not clearly described, although groups received different
treatment regimens
No placebo
Blinding of assessors? High risk Not done
Incomplete outcome da-
ta?
Unclear risk Number of dropouts was reported: 10% were lost to follow-up, not an inten-
tion-to-treat analysis
Selective outcome report-
ing?
Unclear risk Adverse events were not reported
Other sources of bias? Low risk No other potential risk of bias
De Diego 1998  (Continued)
 
 
Methods Randomised, controlled, open-label trial parallel-group design
Intention-to-treat analysis: yes
Participants The trial was conducted in 12 university hospitals in Japan. 150 participants randomly assigned to
prednisolone group (66) or prednisolone and valaciclovir group (84). All participants received treat-
ment within 7 days of onset of Bell's palsy.
Age range: > 15 years. The mean age in the valaciclovir plus prednisolone group was 54.5 (SD 17.3) and
58% of these participants were women. In the prednisolone group the mean age was 47.0 (SD 18.6) and
62% were women.
Inclusion criteria
• Patients with Bell's palsy treated within 7 days of onset, no other initial treatment
Exclusion criteria
• Ramsay-Hunt-Syndrom• Contraindications for treatment with prednisolone or valaciclovir• Severe diabetes mellitus• Psychologic disease• Pregnancy• Peptic ulcer• Connective tissue disease• Renal dysfunction
Interventions Participants received either 20 mg prednisolone 3 times daily for 5 days, then 10 mg 3 times daily for
2 days, then 10 mg daily for 2 days plus valaciclovir 500 mg twice daily for 5 days or prednisolone (the
same regimen) alone
Outcomes • Virological examination for anti-herpes simplex virus and anti-varicella zoster virus antibodies• Detection of herpes simplex virus and herpes zoster virus reactivation
Facial movement and recovery measured using the Yanagihara rating scale (Yanagihara 1977), defined
as a score of ≥ 36
Kawaguchi 2007 
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Follow-up for 6 months at 1 and 2 weeks after treatment and then at 1, 2, 3, 4, 5, and 6 months after
treatment
Frequency of incomplete recovery at end of the study and adverse events. Final outcomes reported at 6
months
Funding Partly funded by a Grant-in-Aid for Scientific Research, Ministry of Education, Science and Culture,
Japan
Conflicts of interest No information given
Date conducted October 2002 to January 2005
Notes Multicentre: 12 university hospitals
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The patients were randomly assigned to one of the treatment groups
by simple randomisation."
Comment: the method of generating the random sequence is not described
Allocation concealment
(selection bias)
High risk Not used; when participants were entered into the trial, the allocation enve-
lope contained the name of the treatment group
Blinding of participants? High risk Not done
Blinding of assessors? High risk Not done
Incomplete outcome da-
ta?
Low risk Numbers of participants who did not complete clearly documented: 10% were
lost to follow-up
Selective outcome report-
ing?
High risk Frequency of incomplete recovery at end of the study and adverse events not
reported in the paper
Other sources of bias? Low risk No other potential sources of bias identified
Kawaguchi 2007  (Continued)
 
 
Methods Double-blind, placebo-controlled, randomised, 2 x 2 factorial trial
Participants 551 participants randomised; 496 included in final outcome assessment. Referred for assessment and
treatment within 72 hours of paralysis onset. All participants aged 16 or older and no contraindications
to corticosteroids or antivirals. The mean age was 44.0 ± 16.4.
Patients were recruited in primary and secondary care setting and treated in 17 hospitals in Scotland,
UK. Patients were recruited through their family doctors, emergency departments, the national 24-
hour medical telephone consultancy service, and dentists' offices.
Inclusion criteria
• Unilateral facial nerve weakness of no identifiable cause who presented to primary care or the emer-
gency department and could be referred to a collaborating otorhinolaryngologist within 72 hours af-
ter the onset of symptoms
Exclusion criteria
Sullivan 2007 
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• Pregnancy• Breastfeeding• Uncontrolled diabetes (glycated haemoglobin level, > 8%)• Peptic ulcer disease• Suppurative otitis media• Herpes zoster• Multiple sclerosis• Systemic infection• Sarcoidosis and other rare conditions• An inability to provide informed consent
Interventions Participants allocated to 1 of 4 treatment groups: either aciclovir, prednisolone, both agents, or place-
bo. Participants received prednisolone 25 mg twice daily for 10 days or aciclovir 400 mg 5 times daily
for 10 days, both treatments, or neither treatment, depending upon allocation
Outcomes Primary outcome
• Recovery, rated on House-Brackmann scale (House 1983; House 1985), where recovery was Grade 1
Secondary outcomes
• Health-related quality of life• Health Utilities Index Mark 3• Facial appearance (Derriford Appearance Scale; Harris 2001)• Pain• Adverse outcomes
Frequency of incomplete recovery at end of study was recorded.
Follow-up at 3 months and 9 months. Final outcomes reported at 9 months
Funding Supported by a grant (02/09/04) from the Health Technology Assessment Programme of the National
Institute for Health Research (Department of Health, England). The Scottish School of Primary Care was
funded by the Scottish Executive (Chief Scientist Office and National Health Service Education for Scot-
land) during the study. Practices were reimbursed for their contributions through national Support for
Science mechanisms
Conflicts of interest Drs. Sullivan and Donnan report receiving grant support from GlaxoSmithKline for projects unrelated to
this trial. No other potential conflict of interest relevant to this article was reported.
Date conducted June 2004 to June 2006
Notes Multicentre: 17 hospitals
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "...patient was randomly assigned to a study group by an independent,
secure, automated telephone randomisation service."
Allocation concealment
(selection bias)
Low risk All parties blinded to allocation
Blinding of participants? Low risk Participants not receiving active drug received placebo. All administered med-
ication identical and in identical containers
Sullivan 2007  (Continued)
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Blinding of assessors? Low risk Assessors blinded to treatment group
Incomplete outcome da-
ta?
Low risk All participants who were unable to complete were documented - both fre-
quency and reason. Intention-to-treat analysis performed
Selective outcome report-
ing?
Low risk All planned outcome measures reported
Other sources of bias? Low risk No other potential sources of bias identified
Sullivan 2007  (Continued)
 
 
Methods Randomised, placebo-controlled, single-blind study, two parallel groups
Participants 296 participants were recruited in six university hospitals in Japan, 221 randomised: 114 to valaciclovir
and prednisolone, 107 to placebo and prednisolone. All participants commenced treatment within 7
days of onset of palsy.
Age range: > 15 years. The mean age was 48.4 (range 15-80) in the valaciclovir plus prednisolone group
and 52.3 (15-84) in the prednisolone plus placebo group. Of the AS group 48% and of the OS group 47%
were women.
Inclusion criteria
• Patients with Bell's palsy who were treated within 7 days of the onset• No contraindications to antivirals or corticosteroids
Exclusion criteria
• Facial palsy attributable to central nervous system disorders, neoplasms, otitis media, trauma, Ram-
say Hunt syndrome, or zoster sine herpete, which is a form of Ramsay Hunt syndrome without mani-
festation of herpetic vesicles at the auricle or ear canal
Interventions Randomised to receive prednisolone 60 mg for 5 days, 30 mg for 3 days, and 10 mg for 2 days ± valaci-
clovir 1000 mg/day for 5 days. Following corticosteroids, all participants received methylcobalamin
1500 µg per day for 6 months or until complete recovery
Outcomes Primary outcome
• Full recovery based on a score of ≥ 36 on the Yanagihara scale (Yanagihara 1977) (conversion scale to
House-Brackmann scale included in paper; House 1983; House 1985)
Follow-up at 1, 3, and 6 months after commencing treatment. Final outcomes reported at 6 months
Funding Granted by the Ministry of Education, Culture, Sports, Science and Technology of Japan
Conflicts of interest No information given
Date conducted February 2002 to March 2004
Notes Multicentre: 6 academic tertiary referral centres. 23 participants were excluded after randomisation be-
cause of herpes zoster; 52 were lost to follow-up (25.3%). Frequency and reasons for dropout of partici-
pants who did not complete the study were documented
Risk of bias
Bias Authors' judgement Support for judgement
Hato 2007 
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Random sequence genera-
tion (selection bias)
Unclear risk Quote: "the patients were randomly divided into two groups using the enve-
lope method". Randomisation was carried out without stratification. No cen-
tral randomisation
Allocation concealment
(selection bias)
Unclear risk Participants were assigned to one of the groups by moderators, but the alloca-
tion concealment was not clearly described
Blinding of participants? High risk Inadequate. Participants blinded to treatment, but different treatments with
different frequencies meant that true blinding was not achieved
Blinding of assessors? High risk Not done. Assessors were not blinded to treatment
Incomplete outcome da-
ta?
High risk Frequency and reasons for dropouts documented. High dropout rate reported;
25.3%. Intention-to-treat analysis performed
Selective outcome report-
ing?
Low risk Main outcome measures, adverse events all reported
Other sources of bias? Unclear risk Statistical tests employed not clearly stated
Hato 2007  (Continued)
 
 
Methods Randomised, placebo-controlled double-blind trial with 2x2 factorial design
Participants This trial in 829 participants was carried out in 16 otorhinolaryngological centres in Sweden and one in
Finland. Participants were randomised within 72 hours of facial palsy onset.
Age range: 18 to 75 years
The mean age was 42 in the prednisolone plus valaciclovir group and 38 in the prednisolone plus place-
bo group (range 31-54). In the AS group 39% and in the OS group 42% were women.
Inclusion criteria
• Participants were randomised within 72 hours of facial palsy onset• No contraindications to corticosteroid or antivirals
Exclusion criteria
• Systemic anti-herpetic medication within the past 2 weeks• Ongoing systemic corticosteroid medication• Allergy to aciclovir, valaciclovir, famciclovir, or ganciclovir• Pregnancy• Breastfeeding• Being a woman of child-bearing age who was unwilling to use contraceptives during the medication
period• Other neurological diseases• Diabetes• Badly controlled hypertension• Current or a history of serious heart disease• History of renal or hepatic disease• Gastric or duodenal ulcer• History of glaucoma, acute otitis or history of ipsilateral chronic otitis• History of tuberculosis• History of immunodeficiency syndromes
Engström 2008 
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• Recent head injury, psychiatric disease, or any other condition that was at risk of being influenced by
the study medication or that might have affected completion of the study
Interventions Participants allocated into 1 of 4 treatment groups: valaciclovir with prednisolone, valaciclovir with
placebo, placebo with prednisolone, or double placebo
Dosages: valaciclovir 1000 mg 3 times daily for 7 days; prednisolone 60 mg daily for 5 days
Outcomes Primary outcome
• Recovery of facial function, as assessed at all visits with the Sunnybrook scale (Ross 1996) and the
House-Brackmann scale (House 1983; House 1985). Complete recovery was taken as Sunnybrook
scale 100 and House-Brackmann scale Grade 1
Other outcomes
• Degree of pain, as recorded during the first 2 months• Adverse events recorded for the first month• Frequency of severe pain, synkinesis, facial spasm, and residual facial symptoms at 12 months
Follow-up at 2 weeks, 1, 2, 3, 6, and 12 months after randomisation, according to recovery. Final out-
comes reported at 12 months
Funding GlaxoSmithKline and Pfizer (Sweden)
Conflicts of interest Information not given
Date conducted May 2001 to September 2006
Notes Multicentre
Some secondary outcomes were reported in papers published separately (Axelsson 2012; Berg 2012)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "...randomization code was developed by Glaxo Wellcome GmBH, with
a computer number generator to select random permuted blocks of eight"
Allocation concealment
(selection bias)
Low risk Randomisation code double-blind and held by a third party. Medication dis-
pensed in identical containers to conceal allocation
Blinding of participants? Low risk Study drugs issued in identical containers. All participants blinded to treat-
ment group until study completion
Blinding of assessors? Low risk All study personnel and data analysts blinded to treatment group until study
completion
Incomplete outcome da-
ta?
Low risk Numbers lost to follow-up and reasons given. Modified intention-to-treat
analysis (829 of the 839 participants included)
Selective outcome report-
ing?
Low risk All primary outcomes reported. Other outcomes were reported in another pa-
per due to space constrictions
Other sources of bias? Low risk No other potential sources of bias identified
Engström 2008  (Continued)
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Methods Randomised controlled, open-label trial with two parallel groups
Although the main outcome was defined as complete recovery at three months, only 47 were assessed
as planned. The rest of them returned before month three or after month 12. Data of these 47 patients
were sent by the author
Participants 167 patients with facial paralysis of 18 years and older in the trial within 5 days after onset; 50 patients
were lost to follow-up and only 127 were analysed. The mean age was 40.6 ± 20.5 in the prednisolone
group and 42.6 ± 30.9 in the combined treatment group. The study was carried out in the Department
of Neurology, University Hospital of Bonn, Germany
Inclusion criteria
• Patients with acute untreated facial paralysis palsy
Exclusion criteria
• Contraindications to corticosteroid or famciclovir therapy were peptic ulcer, insulin-dependent di-
abetes mellitus, renal or hepatic dysfunction, immune suppression, and pregnancy, Lyme disease,
zoster oticus, or other symptomatic causes
Interventions Patients admitted on even dates were assigned to prednisone, patients admitted on odd dates to pred-
nisone and famciclovir. Of the prednisolone 1 mg/kg body weight was given for 4 days, and was subse-
quently tapered over the following 8 days; famciclovir was administered orally three times per day (250
mg) for 7 days. All patients received H2-receptor blockers, artificial tears and ophthalmic ointment for
eye care. Follow-up visit: 3 months after onset of Bell's palsy
Outcomes Complete recovery at three months. The assessors in the trial used the House-Brackman scale (House
1983; House 1985), or a similar score and complete recovery was not defined
Funding No information given
Conflicts of interest The authors declare no conflict of interest
Date conducted January 2001 to June 2005
Notes Single-centre
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Even days and odd days
Allocation concealment
(selection bias)
High risk The trial was not blinded
Blinding of participants? High risk No blinding
Blinding of assessors? High risk No blinding
Incomplete outcome da-
ta?
High risk Of the 167 participants, 50 were lost to follow-up, most of them in the com-
bined treatment group. Only 47 participants were assessed within the defined
time period. No intention-to-treat analysis
Selective outcome report-
ing?
Unclear risk Not identified
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Other sources of bias? Unclear risk It looks as if the dates for reassessment were not clearly communicated to the
patients.
Unclear why more patients in the combination treatment group were lost to
follow-up
Minnerop 2008  (Continued)
 
 
Methods Double-blind, placebo-controlled, randomised trial. Two parallel groups
Participants Included 42 participants assigned to 2 treatment groups. Participants with other causes of facial palsy
were excluded
Age range was 14-82 years and the mean age was 42.5 ± 20.8 in the combined treatment group 40.1 ±
18.5 in the prednisolone group. Patients were recruited in Neurología del Hospital de Clínicas de Mon-
tevideo in Uruguay.
Inclusion criteria
• Acute onset of facial paralysis in patients > 14 years, not associated with neurological or systemic
diseases, otologic or parotid diseases, traumatic brain injury, tumours of the region or herpes zoster
oticus
Exclusion criteria
• Chronic kidney disease• HIV infection• Tuberculosis• Pregnant or breastfeeding women• Hypertonus > 160/100 mmHg• Peptic ulcer• Glaucoma• Decompensated heart failure• Ramsay-Hunt Syndrom
Interventions Randomised to receive either valaciclovir plus prednisone or prednisone plus placebo. Both groups re-
ceived 1 mg/kg weight prednisone for 7 days, then reduced doses for 14 days
Participants in the treatment group received 2 g valaciclovir for 7 days
All participants undertook eye protection and received rehabilitation
Outcomes Primary outcome
• Recovery on facial grading system (Sunnybrook scale; Ross 1996), where recovery was taken as > 90
Follow-up at 1, 2, 4, 8, and 12 months. Final outcomes reported at 6 months
Adverse events were not reported
Funding Information not given
Conflicts of interest Information not given
Date conducted December 2002 to December 2003
Notes Single-centre
Vázquez 2008 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Simple randomisation, not specified
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding of participants? Unclear risk Different treatment regimens in both groups, blinding and usage of placebo
not described
Blinding of assessors? Unclear risk Blinding method of the assessors not clearly described
Incomplete outcome da-
ta?
Low risk All outcome data were reported
Selective outcome report-
ing?
Unclear risk All planned outcome measures reported; authors reported synkinesis and ad-
verse effects, but without assigning the cases to the groups
Other sources of bias? Low risk No other potential sources of bias identified
Vázquez 2008  (Continued)
 
 
Methods Randomised, double-blind, controlled trial, 2 parallel groups
Participants 91 participants; other causes of facial palsy were excluded. No maximum period after onset stated, but
actual time to treatment recorded. All participants were admitted to hospital and received physical
therapy and plasma volume expanders as adjuncts. The trial was carried out in the Department of Oto-
laryngology, College of Medicine, Kyung Hee University,
South Korea.
Mean age in the aciclovir and prednisolone group was 42.7 ± 15.7 years, prednisolone group: 40.2 ± 18.4
years
Inclusion criteria
• Peripheral facial palsy that developed suddenly (age or age range was not given)
Exclusion criteria
• Patients with central nervous system abnormalities, neoplasms, acute or chronic middle ear disease• Patients with facial palsy caused by temporal bone fracture• Patients with facial nerve paralysis caused by surgery• Patients with Ramsay Hunt syndrome• Those who could not be treated with corticosteroids or aciclovir because of uncontrollable diabetes
or duodenal ulcer
Interventions Randomised to receive either aciclovir and prednisolone or prednisolone alone. Aciclovir given at a
dose of 2400 mg/day for 5 days. Prednisolone given as 1 mg/kg/day for 5 days, then tapered on days
6 to 10. All participants admitted to hospital and received physical therapy (facial massage and treat-
ment with an electrical stimulator, together with facial expression practice) and plasma volume ex-
panders as adjuncts. All patients were administered eye ointment to prevent ocular injury.
Outcomes Primary outcome
Yeo 2008 
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• Recovery on House-Brackmann scale (House 1983; House 1985), where recovery was Grade ≤ 2
Subgroup analysis of early versus delayed treatment
Follow-up at 2 and 6 months. Final outcomes reported at 6 months
Funding No information given
Conflicts of interest No information given
Date conducted January 2003 to July 2006
Notes Single-centre. All participants admitted
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk States 'randomised' in study title, but no description of this in the paper
Allocation concealment
(selection bias)
Unclear risk No clear statement of this in the study
Blinding of participants? Unclear risk States 'double-blind' in study title, but no description of methods employed
for this in text
Blinding of assessors? Unclear risk States 'double-blind' in study title, but no description of methods employed
for this in text
Incomplete outcome da-
ta?
Unclear risk Incomplete follow-up data not mentioned in the study. No intention-to-treat
population described
Selective outcome report-
ing?
Unclear risk Stated primary outcome measure reported, no adverse events reported
Other sources of bias? Low risk No further potential risks
Yeo 2008  (Continued)
 
 
Methods Randomised-controlled, open-label trial, two parallel groups
Participants 107 clinic patients of 15 years and older with unilateral facial paralysis of unknown cause were recruit-
ed and 68 were analysed. Of these patients, 33 had exclusion criteria and 9 were lost to follow-up so
that data of 68 patients were analysed. The trial was carried out in the Department of Neurology in
Bangabandu Sheikh Mujib Medical University.
Inclusion criteria
• Untreated acute Bell's palsy. The mean age was 31+/- 9.6 years and in the prednisolone plus aciclovir
group and 35.1 +/- 11.7 in the prednisolone group
Exclusion criteria:
• Abnormalities of central nervous system, neoplasm, acute ore chronic middle ear disease, temporal
bone fracture, Bell’s palsy with vesicle, uncontrolled diabetes, duodenal ulcer
Shahidullah 2011 
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Interventions Famiciclovir (250 mg three times a day for 5 days) plus prednisolone (60 mg a day 7 days) or pred-
nisolone alone (60 mg a day for 7 days). All patients received H2-receptor blocker, artificial tears and
ophthalmic ointment for eye care.
Outcomes Complete recovery of facial function at the end of study. Patients were assessed at baseline using the
House-Brackman scale (House 1983; House 1985), and were followed up one week, one month and
three months after inclusion. Complete recovery was defined as House-Brackman Grade 1
Funding Information not given
Conflicts of interest Information not given
Date conducted July 2008 to June 2009
Notes Single-centre
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Patients were randomised based on odd and even numbers
Allocation concealment
(selection bias)
Unclear risk Not clearly described
Blinding of participants? High risk No blinding
Blinding of assessors? High risk No blinding
Incomplete outcome da-
ta?
High risk Per protocol analysis only. 27% of the participants were either excluded or lost
to follow-up. No intention-to-treat analysis
Selective outcome report-
ing?
Low risk Not identified
Other sources of bias? High risk The tests used to assess Bell's palsy were not adequately described. There
were more participants with severe Bell's palsy in the combination group than
in the prednisolone alone group.
Shahidullah 2011  (Continued)
 
 
Methods Randomised, controlled, double-blind study, parallel-group design
Participants 269 participants with severe Bell's palsy were recruited; 206 were included in the final analysis. 99
participants were assigned to the famciclovir and prednisolone group, 107 participants to the pred-
nisolone group. The mean age was 46.7 (SD 16.2) years in the AS group and 48.6 (SD 15.1) in the OS
group. Half of the AS group (50%) and 52% of the OS group were female. The authors state that there
was no difference between both groups. All participants received treatment within 7 days of onset of
palsy. Age range: 16-77 years
Inclusion criteria
• Acute unilateral peripheral facial paralysis without skin lesions or intraoral lesions occurring within
7 days of presentation
Lee 2013 
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• Only patients with severe-to-complete Bell's palsy (House-Brackmann scale Grade 5 or more) were
enrolled
Exclusion criteria
• Bell's palsy that occurred more than 7 days before presentation• Suspected Ramsay-Hunt syndrome• Meningitis• Myelitis• Vasculopathy• Patients who could not be observed for at least 6 months• Initial use of several different types of treatments• Pregnancy or breastfeeding• Uncontrolled diabetes or hypertension• Poor general medical conditions in which corticosteroid or antiviral therapy cannot be used• Suspicion of Borrelia infection• Tendency for neuropsychiatric disease• Refusal to participate in the study
Interventions AS group: prednisolone 64 mg for 4 days, 48 mg for 2 days, 32 mg for 2 days, and 16 mg for 2 days with
famciclovir 750 mg/day for 7 days intravenously (N = 99)
OS group: famciclovir 750 mg/day for 7 days intravenously (N = 107). Both drugs were given simultane-
ously
Outcomes Primary outcome
• Full recovery, based on the House-Brackmann scale (Grades 1 and 2) at 6 months (House 1983; House
1985)
Evaluation of prognostic factors for incomplete recovery. Follow-up at 2 weeks and 6 months after
commencing treatment
Funding Kyung Hee University Research Fund
Conflicts of interest The authors state having no conflict of interest
Date conducted September 2008 to August 2011
Notes Single-centre, Department of Otopharyngology at the Kyung Hee University in Korea
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random sequence generation using computer codes
Allocation concealment
(selection bias)
Unclear risk No information on concealment
Blinding of participants? High risk No placebo. No information on concealment of the intervention
Blinding of assessors? High risk Different treatment regimens in both groups. No information on concealment
of the intervention
Lee 2013  (Continued)
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Incomplete outcome da-
ta?
High risk Per protocol analysis only. Dropout rate reported: 13.1%. No intention-to-treat
analysis
Selective outcome report-
ing?
Unclear risk Adverse events were not reported
Other sources of bias? Unclear risk Two participants with adverse events in the corticosteroid group (not clearly
specified) were excluded from the analysis
Lee 2013  (Continued)
 
 
Methods Randomised, controlled, not blinded trial, parallel-group design
Participants This study was conducted in the Department of Pediatrics, Children and Adolescent Health in Zahedan,
Iran. 43 children between 2 and 18 years were randomly assigned in the prednisolone and aciclovir
group (N = 20) or in the prednisolone group (N = 23). Participants received treatment within three days
of onset of Bell's palsy. The mean age was 8.4 (SD 4.9) in the AS group and 8.6 years (SD 5.1) in the OS
group. More female patients were in the AS group than in the OS group (55% versus 39%).
Inclusion criteria
• Acute unilateral peripheral facial palsy
Exclusion criteria
• Patients with paralysis of other cranial nerves• Passing more than 3 days of symptoms onset• Patients less than 2 years of age and older than 18 years• Presence of secondary causes of the 7th nerve palsy• Suspicion of meningitis, vasculopathy, Ramsey Hunt syndrome, peptic ulcer• Anti-herpetic treatment within the last 2 weeks• Sensitivity to aciclovir
Interventions The participants were treated with either a combination of 2 mg/kg/day prednisolone and 10 mg/kg/
day aciclovir every eight hours for seven days or with prednisolone alone following the same scheme.
Outcomes Primary outcome
• Severity of Bell's palsy on the House-Brackmann scale (House 1983; House 1985)
Secondary outcomes
• Not reported
Funding No information given
Conflicts of interest The authors declare no conflict of interest
Date conducted September 2011 to March 2014
Notes The paper provides little information on trial methods and procedures
Risk of bias
Bias Authors' judgement Support for judgement
Khajeh 2015 
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Random sequence genera-
tion (selection bias)
Unclear risk Sequence generation not stated, randomisation procedure not described
Allocation concealment
(selection bias)
Unclear risk Not described by the authors
Blinding of participants? High risk No blinding
Blinding of assessors? High risk No blinding
Incomplete outcome da-
ta?
Unclear risk Number of participants lost to follow-up not given. Unclear whether inten-
tion-to-treat analysis was performed
Selective outcome report-
ing?
Unclear risk Only one outcome was predefined
Other sources of bias? Unclear risk Trial procedures poorly reported
Khajeh 2015  (Continued)
 
 
Methods Randomised, controlled trial, parallel-group design, unclear whether blinded or not
Participants The trial was conducted in the Neuropsychiatry Department of the Assiut University hospital in Egypt.
65 patients between 15 to 60 years with one-sided Bell's palsy were recruited within three days of on-
set. Fifteen patients were excluded due to exclusion criteria. The mean age of the patients in the aci-
clovir plus prednisolone group was 36.3 (SD 14.0) and 37.4 (SD 13.4) in the prednisolone group. Data on
sex are missing.
Inclusion criteria
• Patients with acute onset facial palsy (unilateral) and within the first 3 days of onset
Exclusion criteria
• Patients with brittle diabetes mellitus• Morbid obesity• Renal or liver impairment• Osteopenia• Pregnancy• Breastfeeding• Uncontrolled hypertension• Prior history of corticosteroid intolerance
Interventions Prednisolone 60 mg a day and aciclovir 400 mg three times a day were given in the intervention group
and prednisolone 60 mg a day alone in the control group within three days after onset. The treatment
lasted seven days for prednisolone and five days for aciclovir.
Outcomes Primary outcome
• Change in House-Brackmann scale three months after palsy onset (House 1983; House 1985)
Outcome data were assessed at baseline, two weeks, two and three months after inclusion. Complete
recovery was defined as Grades 1 and 2
Funding No information given
Khedr 2016 
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Conflicts of interest Authors declare having no conflict of interest
Date conducted April 2014 to December 2014
Notes Single-centre
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Patients were randomised in two groups using serially-numbered opaque
closed envelopes. The method of generating the random sequence is not de-
scribed
Allocation concealment
(selection bias)
Unclear risk Patients were randomised in two groups using serially-numbered opaque
closed envelopes
Blinding of participants? Unclear risk The study was stated as blinded but the masking procedure was not de-
scribed. The authors describe it as follows: Quote: "...although this was not
placebo-controlled trial, since it was an add-on design to test the effect of ad-
ministering an antiviral drug, participants did not know who was getting the
antiviral and who was not."
Blinding of assessors? Unclear risk It is not clearly described how assessors were blinded. Especially as it is not
clear whether patients were blinded sufficiently. The authors stated that:
Quote: "To ensure double blinding, the random allocation sequence was kept
by a different investigator to the one who enrolled the participants (neurolo-
gist). Moreover, a third investigator was responsible for following up the pa-
tients and for assessment (rehabilitation doctor).”
Incomplete outcome da-
ta?
Low risk Patients with mild to moderate Bell's palsy and obesity were excluded at inclu-
sion but of the participants randomised, only two were lost to follow-up. No in-
tention-to-treat analysis
Selective outcome report-
ing?
High risk Adverse events were not reported
Other sources of bias? Low risk Not identified
Khedr 2016  (Continued)
AS: antivirals plus corticosteroids
OS: corticosteroids alone or in combination with placebo
SD: standard deviation
 
Characteristics of excluded studies [ordered by year of study]
 
Study Reason for exclusion
Ramos Macias 1992 Inadequate allocation concealment. No information reported about methods of randomisation, di-
agnostic criteria used, length of follow-up, or number of participants lost to follow-up. Thirty-three
percent had Ramsay Hunt syndrome, abstract only available
Ibarrondo 1999 Retrospective study. 100 participants collected between 1983 and 1989 received corticotherapy.
100 participants treated after 1989 received aciclovir
Abdelghany 2013 Study retracted
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Study Reason for exclusion
Zhou 1999 Prospective study. 69 participants with Bell's palsy followed up for only 2 weeks. Not double-blind,
and allocation concealment not described. Used own scale for palsy grading, outcome measures
not met. Did report adverse events. Four participants receiving aciclovir treatment had gastric
malaise
Antunes 2000 Small-study numbers and insufficient information in original paper to assign a participant with in-
complete recovery to the correct control group. Author contacted by Dr D Allen, but no response
received
de Aquino 2001 Methodology not clear from original paper. An author of a previous version of this review (D Allen)
attempted to obtain further information but obtained no response
Inanli 2001 The paper was not available
Hato 2003 Retrospective analysis of treatment
Axelsson 2003 Use of a historical control group
Chen 2005 Follow-up data for only 4 weeks from palsy onset
Roy 2005 Inadequate information on outcome data, 22% lost to follow-up, abstract only published in journal
supplement and not traced as a full publication
Hultcrantz 2005 Allocation was not randomised
Ahangar 2006 Allocation was not randomised
Kang 2015 Prospective, not randomised, not controlled study comparing antiviral agents plus prednisolone
with prednisolone alone in participants with Bell's palsy
Ferreira 2016 A prospective single-blinded study comparing corticosteroids and neuromuscular training with fa-
cial neuromuscular training alone in participants with Bell's palsy
 
Characteristics of studies awaiting assessment [ordered by year of study]
 
Methods Randomised, parallel-assignment, open-label
Participants Inclusion criteria: People with Bell's palsy, age over 10 years
Exclusion criteria: more than 7 days have passed since the onset of paralysis; finding another
cause for the paralysis
Target sample size 180
Interventions Group 1: prednisone 1 mg/kg body weight daily for 3 days. The treatment was tapered over the
next 12 days
Group 2: aciclovir, 400 mg every 5 hours per day for 10 days
Group 3: combination of aciclovir and prednisone
Outcomes Primary: House-Brackmann scale every 15 days
Treatment failure (no reduction of House-Brackmann scale) at the end of month 3
Notes Monocentre study, Arak University of Medical Sciences, Iran. Contact: dr.ashtiani@arakmu.ac.ir
IRCT201109187575N1 
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First enrolment in 2010
Recruitment reported to be complete
IRCT201109187575N1  (Continued)
 
Characteristics of ongoing studies [ordered by year of study]
 
Trial name or title Bell's palsy in children: a multicentre, double-blind, randomised, placebo-controlled trial to deter-
mine whether prednisolone improves recovery at 1 month
Methods Multicentre, double-blind, randomised, placebo-controlled
Participants Children (6 months to 18 years old) with Bell's palsy (diagnosed by treating doctor) of acute onset
within 72 hours of randomisation
Planned recruitment 270 per group (540 in total) to allow for 10% loss to follow-up at 1 month
Exclusion criteria
• Previous episode of Bell's Palsy or previously randomised in the study• Contraindication to prednisolone• Current systemic or inhaled steroid use, or use within 2 weeks prior to symptom onset• Current or past oncological diagnosis• Blood test result (if obtained during this illness) potentially indicative of leukaemia• Pregnancy and/or lactation• Currently receiving medications with which concomitant use of prednisolone is contraindicated• Live vaccination within the previous 1 month or requirement for live vaccine within 6 weeks of 1st
prednisolone dose• Signs of upper motor neuron facial nerve palsy (weakness of lower half of the face only)• Current or recent (1 week prior to Bell's palsy symptoms) otitis media• Evidence of vesicles on the ear or vesicles or ulcers elsewhere on the body suggestive of recent
herpes simplex, herpes zoster or chickenpox• Significant facial trauma in the week prior to appearance of symptoms• Referred to GP clinic in Emergency Department or failed to wait• Unable to attend a follow-up visit in one month's time• Any other condition at risk of being influenced by study treatment or completion• Parents unable to comply with the study, or with insufficient understanding
Interventions Prednisolone 1 mg/kg/day (dosing based on weight categories) up to a maximum of 50 mg/day for
10 days.
Placebo (identical in look and taste, in identical glass bottles)
Both prednisolone and placebo given as a once daily dose via oral solution
Outcomes Primary outcomes
• Complete recovery at 1 month post-randomisation, where recovery is defined as a House-Brack-
mann facial grading score of 1. Recovery assessed in person by a specialist clinician
Secondary outcomes
• Complete recovery at 1, 3 and 6 months, using the Sunnybrook Facial Grading System (Ross 1996)
and the House-Brackmann facial grading scale (House 1983; House 1985, assessed by a specialist
physician
ACTRN12615000563561 
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• Parent/guardian and participant (where aged > 8 years) perception) of facial nerve recovery at 1,
3 and 6 months, using a lay translation of the House-Brackmann facial grading scale• Quality of life: emotional and functional well-being of the participant assessed by the par-
ent/guardian and participant using the Pediatric Quality of Life Inventory scale, the Child Health
Utility 9D scale and sections of the Harter scale at 1, 3 and 6 months postrandomisation• Pain (on 0 to 10 scales), assessed using child-assigned visual analogue scale (VAS), or Faces Pain
Scale Revised (for participants aged 5 and older) and using parent-assigned VAS for participants
at any age, at 1, 3 and 6 months postrandomisation• Prevalence of sykinesis or autonomic dysfunction using the Sunnybrook scale augmented by a
synkinesis assessment questionnaire, assessed by a specialist clinician and/or research assistant
at 1, 3 and 6 months postrandomisation• Health utilisation costs assessed via Child Health Utility 9D and via capture of cost information
from the parent/guardian/participant related to inpatient, outpatient, or emergency department
visits and to any other health facilities, including general practitioner attendance for treatment
or investigation 6 months following randomisation
Starting date First enrolment: 13 October 2015
Contact information A/Prof Franz Babl, Emergency Research Department, Murdoch Children's Research Institute,
Flemingon Road, Parkville, VIC 3052
Notes Multicentre, Australia and New Zealand
ACTRN12615000563561  (Continued)
 
 
Trial name or title Evaluation of cortisone treatment in children with acute facial nerve palsy (FACE)
Methods Randomised, parallel assignment, quadruple-blind (participant, care provider, investigator, out-
come assessor), phase IV RCT
Participants Children with acute peripheral unilateral facial palsy
Inclusion criteria
• 1 to 17 years old• Acute peripheral unilateral facial nerve palsy• Less than 72 hours since debut of symptoms• Signed informed consent
Exclusion criteria
• Head trauma < 1 month• Central or bilateral facial nerve palsy• Malformations in head and neck• Conditions not compatible with cortisone treatment• Current or past oncological diagnosis• Other serious medical conditions (meningitis, encephalitis, stroke)• Acute otitis media• Signs of herpes simplex or varicella zoster infection (vesicles in the ear region)• Pregnancy or breastfeeding• Use of any systemic or inhaled steroids within 2 weeks prior to onset of symptoms• Immunisation with live vaccine 1 month prior to onset of symptoms• Requirement of live vaccine within 2 months from start of experimental treatment (prednisolone
or placebo)• Evaluation of primary endpoint at 12 months not feasible for any reason
NCT03781700 
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• Previously included into the FACE study
Interventions Prednisolone 5 mg tablets, 1 mg/kg bodyweight orally per day for 10 days, maximum 50 mg per day
Placebo: oral tablet identical in appearance
Outcomes Primary outcomes
• Total recovery assessed on the House-Brackmann scale at 12 months (+/- 2 weeks) after inclusion
(a scale where I is normal function and VI is total loss of function)
Secondary outcomes
• Total recovery assessed on the Sunnybrook Facial Grading System (Ross 1996) at 12 months (+/-
2 weeks) after inclusion (a scale where 100 is normal function and 0 is total loss of function)• Facial Disability Index (FDI) at 12 months (+/- 2 weeks) after inclusion (a scale with 5 functional
domains: 5 means no problems and 2 or 1 means problems all the time; and 5 social domains: 6
means problems all the time and 1 means no problems at all)• Facial Clinimetric Evaluation (FaCE) Scale at 12 months (+/- 2 weeks) after inclusion (a scale with
15 functional and social domains: 1 means problems all the time and 5 means no problems at all)• Synkinesis Assessment Questionnaire (SAQ) at 12 months (+/- 2 weeks) after inclusion. This is sub-
jective grading of synkinesis symptoms with 9 functional domains (1 means no problems at all
and 5 means problems all the time)
Adverse events at 12 months (+/- 2 weeks) after inclusion, assessed as number of adverse events
possibly or probably related to the study drug
Starting date 3 May 2019
Contact information Barbro Hedin Skogman: barbro.hedinskogman@ltdalarna.se, Center for Clinical Research Dalarna,
Sweden
Notes Sweden
NCT03781700  (Continued)
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Comparison 1.   Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS):
trials at lower risk of bias
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incomplete recovery at end of
study (trials at lower risk of bias)
3 766 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.38, 1.74]
1.1 Aciclovir 2 350 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.14, 4.31]
1.2 Valaciclovir 1 416 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.60, 1.23]
2 Incomplete recovery at end of
study (full data set)
13 1729 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.38, 0.77]
2.1 Aciclovir 6 580 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.22, 0.83]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.2 Famciclovir 3 321 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.22, 1.06]
2.3 Valaciclovir 4 828 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.08]
3 Incomplete recovery at end of
study in severe cases: data set limit-
ed to trials at lower risk of bias
2 98 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.57, 1.17]
4 Incomplete recovery at end of
study in severe cases: full data set
4 478 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.41, 0.99]
5 Motor synkinesis or crocodile tears 2 469 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.36, 0.87]
6 Adverse events (trials at lower risk
of bias)
2 656 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.81, 1.69]
7 Adverse events (full data set) 4 945 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.83, 1.63]
 
 
Analysis 1.1.   Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS
versus OS): trials at lower risk of bias, Outcome 1 Incomplete recovery at end of study (trials at lower risk of bias).
Study or subgroup Favours AS OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Aciclovir  
Adour 1996 4/53 11/46 26.03% 0.32[0.11,0.92]
Sullivan 2007 9/124 5/127 26.26% 1.84[0.64,5.35]
Subtotal (95% CI) 177 173 52.29% 0.76[0.14,4.31]
Total events: 13 (Favours AS), 16 (OS)  
Heterogeneity: Tau2=1.26; Chi2=5.23, df=1(P=0.02); I2=80.88%  
Test for overall effect: Z=0.31(P=0.76)  
   
1.1.2 Valaciclovir  
Engström 2008 42/206 50/210 47.71% 0.86[0.6,1.23]
Subtotal (95% CI) 206 210 47.71% 0.86[0.6,1.23]
Total events: 42 (Favours AS), 50 (OS)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.84(P=0.4)  
   
Total (95% CI) 383 383 100% 0.81[0.38,1.74]
Total events: 55 (Favours AS), 66 (OS)  
Heterogeneity: Tau2=0.29; Chi2=5.3, df=2(P=0.07); I2=62.24%  
Test for overall effect: Z=0.55(P=0.58)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.9), I2=0%  
Favours AS 100.1 50.2 20.5 1 Favours OS
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Analysis 1.2.   Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment
(AS versus OS): trials at lower risk of bias, Outcome 2 Incomplete recovery at end of study (full data set).
Study or subgroup Favours AS OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Aciclovir  
Adour 1996 4/53 11/46 7.49% 0.32[0.11,0.92]
Li 1997 4/25 13/21 8.68% 0.26[0.1,0.67]
Sullivan 2007 9/124 5/127 7.57% 1.84[0.64,5.35]
Yeo 2008 3/44 7/47 5.77% 0.46[0.13,1.66]
Khajeh 2015 2/20 8/23 4.92% 0.29[0.07,1.2]
Khedr 2016 2/25 8/25 4.82% 0.25[0.06,1.06]
Subtotal (95% CI) 291 289 39.25% 0.43[0.22,0.83]
Total events: 24 (Favours AS), 52 (OS)  
Heterogeneity: Tau2=0.32; Chi2=9.45, df=5(P=0.09); I2=47.07%  
Test for overall effect: Z=2.5(P=0.01)  
   
1.2.2 Famciclovir  
Minnerop 2008 2/22 2/25 3.14% 1.14[0.17,7.41]
Shahidullah 2011 1/34 8/34 2.74% 0.13[0.02,0.95]
Lee 2013 17/99 36/107 15.8% 0.51[0.31,0.85]
Subtotal (95% CI) 155 166 21.68% 0.48[0.22,1.06]
Total events: 20 (Favours AS), 46 (OS)  
Heterogeneity: Tau2=0.16; Chi2=2.61, df=2(P=0.27); I2=23.36%  
Test for overall effect: Z=1.82(P=0.07)  
   
1.2.3 Valaciclovir  
Kawaguchi 2007 8/84 9/66 9.43% 0.7[0.29,1.71]
Hato 2007 4/114 11/107 7.12% 0.34[0.11,1.04]
Vázquez 2008 3/22 2/19 3.78% 1.3[0.24,6.96]
Engström 2008 42/206 50/210 18.74% 0.86[0.6,1.23]
Subtotal (95% CI) 426 402 39.07% 0.79[0.57,1.08]
Total events: 57 (Favours AS), 72 (OS)  
Heterogeneity: Tau2=0; Chi2=2.8, df=3(P=0.42); I2=0%  
Test for overall effect: Z=1.49(P=0.14)  
   
Total (95% CI) 872 857 100% 0.54[0.38,0.77]
Total events: 101 (Favours AS), 170 (OS)  
Heterogeneity: Tau2=0.14; Chi2=20.03, df=12(P=0.07); I2=40.09%  
Test for overall effect: Z=3.4(P=0)  
Test for subgroup differences: Chi2=3.44, df=1 (P=0.18), I2=41.9%  
Favours AS 1000.01 100.1 1 Favours OS
 
 
Analysis 1.3.   Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus
placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 3 Incomplete
recovery at end of study in severe cases: data set limited to trials at lower risk of bias.
Study or subgroup AS OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sullivan 2007 4/21 4/28 7.98% 1.33[0.38,4.72]
Engström 2008 16/26 18/23 92.02% 0.79[0.54,1.14]
   
Favours AS 100.1 50.2 20.5 1 Favours OS
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Study or subgroup AS OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 47 51 100% 0.82[0.57,1.17]
Total events: 20 (AS), 22 (OS)  
Heterogeneity: Tau2=0; Chi2=0.72, df=1(P=0.4); I2=0%  
Test for overall effect: Z=1.09(P=0.28)  
Favours AS 100.1 50.2 20.5 1 Favours OS
 
 
Analysis 1.4.   Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS
versus OS): trials at lower risk of bias, Outcome 4 Incomplete recovery at end of study in severe cases: full data set.
Study or subgroup AS OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Hato 2007 4/92 11/82 12.64% 0.32[0.11,0.98]
Sullivan 2007 4/21 4/28 10.13% 1.33[0.38,4.72]
Engström 2008 16/26 18/23 43.15% 0.79[0.54,1.14]
Lee 2013 17/99 36/107 34.08% 0.51[0.31,0.85]
   
Total (95% CI) 238 240 100% 0.64[0.41,0.99]
Total events: 41 (AS), 69 (OS)  
Heterogeneity: Tau2=0.08; Chi2=5.2, df=3(P=0.16); I2=42.29%  
Test for overall effect: Z=1.99(P=0.05)  
Favours AS 100.1 50.2 20.5 1 Favours OS
 
 
Analysis 1.5.   Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no
treatment (AS versus OS): trials at lower risk of bias, Outcome 5 Motor synkinesis or crocodile tears.
Study or subgroup AS OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Adour 1996 7/53 13/46 30.43% 0.47[0.2,1.07]
Engström 2008 19/184 32/186 69.57% 0.6[0.35,1.02]
   
Total (95% CI) 237 232 100% 0.56[0.36,0.87]
Total events: 26 (AS), 45 (OS)  
Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%  
Test for overall effect: Z=2.55(P=0.01)  
Favours AS 200.05 50.2 1 Favours OS
 
 
Analysis 1.6.   Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no
treatment (AS versus OS): trials at lower risk of bias, Outcome 6 Adverse events (trials at lower risk of bias).
Study or subgroup AS OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sullivan 2007 25/124 24/127 53.1% 1.07[0.65,1.76]
Engström 2008 27/202 21/203 46.9% 1.29[0.76,2.21]
   
Favours AS 50.2 20.5 1 Favours OS
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Study or subgroup AS OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total (95% CI) 326 330 100% 1.17[0.81,1.69]
Total events: 52 (AS), 45 (OS)  
Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%  
Test for overall effect: Z=0.85(P=0.39)  
Favours AS 50.2 20.5 1 Favours OS
 
 
Analysis 1.7.   Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or
no treatment (AS versus OS): trials at lower risk of bias, Outcome 7 Adverse events (full data set).
Study or subgroup AS OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hato 2007 3/114 2/107 3.91% 1.41[0.24,8.26]
Sullivan 2007 25/124 24/127 44.98% 1.07[0.65,1.76]
Engström 2008 27/202 21/203 39.73% 1.29[0.76,2.21]
Shahidullah 2011 6/34 6/34 11.38% 1[0.36,2.79]
   
Total (95% CI) 474 471 100% 1.16[0.83,1.63]
Total events: 61 (AS), 53 (OS)  
Heterogeneity: Tau2=0; Chi2=0.39, df=3(P=0.94); I2=0%  
Test for overall effect: Z=0.87(P=0.39)  
Favours AS 100.1 50.2 20.5 1 Favours OS
 
 
Comparison 2.   Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incomplete recovery at end of study: trials
at lower risk of bias
2 667 Risk Ratio (M-H, Random, 95% CI) 2.69 [0.73, 10.01]
2 Incomplete recovery at end of study: full
data set
3 768 Risk Ratio (M-H, Random, 95% CI) 2.82 [1.09, 7.32]
3 Motor synkinesis and crocodile tears: trials
at lower risk of bias
1 371 Risk Ratio (M-H, Random, 95% CI) 1.70 [1.15, 2.50]
4 Motor synkinesis and crocodile tears: full
data set
2 472 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.08, 2.12]
5 Adverse events 2 658 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.57, 1.28]
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Analysis 2.1.   Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower
risk of bias, Outcome 1 Incomplete recovery at end of study: trials at lower risk of bias.
Study or subgroup AO OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sullivan 2007 27/123 5/127 44.57% 5.58[2.22,14.01]
Engström 2008 74/207 50/210 55.43% 1.5[1.11,2.03]
   
Total (95% CI) 330 337 100% 2.69[0.73,10.01]
Total events: 101 (AO), 55 (OS)  
Heterogeneity: Tau2=0.78; Chi2=7.41, df=1(P=0.01); I2=86.5%  
Test for overall effect: Z=1.48(P=0.14)  
Favours AO 200.05 50.2 1 Favours OS
 
 
Analysis 2.2.   Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials
at lower risk of bias, Outcome 2 Incomplete recovery at end of study: full data set.
Study or subgroup AO OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
De Diego 1998 12/54 3/47 26.03% 3.48[1.05,11.6]
Sullivan 2007 27/123 5/127 31.42% 5.58[2.22,14.01]
Engström 2008 74/207 50/210 42.55% 1.5[1.11,2.03]
   
Total (95% CI) 384 384 100% 2.82[1.09,7.32]
Total events: 113 (AO), 58 (OS)  
Heterogeneity: Tau2=0.53; Chi2=8.78, df=2(P=0.01); I2=77.23%  
Test for overall effect: Z=2.13(P=0.03)  
Favours AO 200.05 50.2 1 Favours OS
 
 
Analysis 2.3.   Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower
risk of bias, Outcome 3 Motor synkinesis and crocodile tears: trials at lower risk of bias.
Study or subgroup AO OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Engström 2008 54/185 32/186 100% 1.7[1.15,2.5]
   
Total (95% CI) 185 186 100% 1.7[1.15,2.5]
Total events: 54 (AO), 32 (OS)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.68(P=0.01)  
Favours AO 50.2 20.5 1 Favours OS
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Analysis 2.4.   Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials
at lower risk of bias, Outcome 4 Motor synkinesis and crocodile tears: full data set.
Study or subgroup AO OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
De Diego 1998 13/54 11/47 26.93% 1.03[0.51,2.07]
Engström 2008 54/185 32/186 73.07% 1.7[1.15,2.5]
   
Total (95% CI) 239 233 100% 1.52[1.08,2.12]
Total events: 67 (AO), 43 (OS)  
Heterogeneity: Tau2=0; Chi2=1.5, df=1(P=0.22); I2=33.34%  
Test for overall effect: Z=2.42(P=0.02)  
Favours AO 50.2 20.5 1 Favours OS
 
 
Analysis 2.5.   Comparison 2 Antivirals versus corticosteroids (AO
versus OS): trials at lower risk of bias, Outcome 5 Adverse events.
Study or subgroup AO OS Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Engström 2008 19/205 21/203 47.19% 0.9[0.5,1.62]
Sullivan 2007 19/123 24/127 52.81% 0.82[0.47,1.41]
   
Total (95% CI) 328 330 100% 0.85[0.57,1.28]
Total events: 38 (AO), 45 (OS)  
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%  
Test for overall effect: Z=0.77(P=0.44)  
Favours AO 50.2 20.5 1 Favours OS
 
 
Comparison 3.   Antivirals plus corticosteroids versus placebo (AS versus OO)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incomplete recovery at end of study 2 658 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.42, 0.76]
2 Motor synkinesis or crocodile tears 1 372 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.23, 0.59]
3 Adverse events 2 649 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.79, 1.65]
 
 
Analysis 3.1.   Comparison 3 Antivirals plus corticosteroids versus
placebo (AS versus OO), Outcome 1 Incomplete recovery at end of study.
Study or subgroup AS OO Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sullivan 2007 9/124 18/122 15.6% 0.49[0.23,1.05]
Engström 2008 42/206 73/206 84.4% 0.58[0.41,0.8]
Favours AS 50.2 20.5 1 Favours OO
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Study or subgroup AS OO Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
Total (95% CI) 330 328 100% 0.56[0.42,0.76]
Total events: 51 (AS), 91 (OO)  
Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.71); I2=0%  
Test for overall effect: Z=3.77(P=0)  
Favours AS 50.2 20.5 1 Favours OO
 
 
Analysis 3.2.   Comparison 3 Antivirals plus corticosteroids versus
placebo (AS versus OO), Outcome 2 Motor synkinesis or crocodile tears.
Study or subgroup AS OO Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Engström 2008 19/184 53/188 100% 0.37[0.23,0.59]
   
Total (95% CI) 184 188 100% 0.37[0.23,0.59]
Total events: 19 (AS), 53 (OO)  
Heterogeneity: Not applicable  
Test for overall effect: Z=4.07(P<0.0001)  
Favours AS 1000.01 100.1 1 Favours OO
 
 
Analysis 3.3.   Comparison 3 Antivirals plus corticosteroids
versus placebo (AS versus OO), Outcome 3 Adverse events.
Study or subgroup AS OO Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sullivan 2007 25/124 20/122 44.58% 1.23[0.72,2.09]
Engström 2008 27/202 25/201 55.42% 1.07[0.65,1.79]
   
Total (95% CI) 326 323 100% 1.14[0.79,1.65]
Total events: 52 (AS), 45 (OO)  
Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%  
Test for overall effect: Z=0.72(P=0.47)  
Favours AS 50.2 20.5 1 Favours OO
 
 
Comparison 4.   Antivirals versus placebo (AO versus OO)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Incomplete recovery at end of study 2 658 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.87, 1.40]
2 Motor synkinesis or crocodile tears 1 373 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.75, 1.43]
3 Adverse events 2 651 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.56, 1.24]
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Analysis 4.1.   Comparison 4 Antivirals versus placebo (AO
versus OO), Outcome 1 Incomplete recovery at end of study.
Study or subgroup AO OO Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Engström 2008 74/207 73/206 80.19% 1.01[0.78,1.31]
Sullivan 2007 27/123 18/122 19.81% 1.49[0.87,2.56]
   
Total (95% CI) 330 328 100% 1.1[0.87,1.4]
Total events: 101 (AO), 91 (OO)  
Heterogeneity: Tau2=0; Chi2=1.63, df=1(P=0.2); I2=38.67%  
Test for overall effect: Z=0.82(P=0.41)  
Favours AO 50.2 20.5 1 Favours OO
 
 
Analysis 4.2.   Comparison 4 Antivirals versus placebo (AO
versus OO), Outcome 2 Motor synkinesis or crocodile tears.
Study or subgroup AO OO Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Engström 2008 54/185 53/188 100% 1.04[0.75,1.43]
   
Total (95% CI) 185 188 100% 1.04[0.75,1.43]
Total events: 54 (AO), 53 (OO)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.83)  
Favours AO 1000.01 100.1 1 Favours OO
 
 
Analysis 4.3.   Comparison 4 Antivirals versus placebo (AO versus OO), Outcome 3 Adverse events.
Study or subgroup AO OO Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Engström 2008 19/205 25/201 55.7% 0.75[0.42,1.31]
Sullivan 2007 19/123 20/122 44.3% 0.94[0.53,1.68]
   
Total (95% CI) 328 323 100% 0.83[0.56,1.24]
Total events: 38 (AO), 45 (OO)  
Heterogeneity: Tau2=0; Chi2=0.33, df=1(P=0.57); I2=0%  
Test for overall effect: Z=0.89(P=0.37)  
Favours AO 50.2 20.5 1 Favours OO
 
 
A D D I T I O N A L   T A B L E S
 
Grade Description
Table 1.   House-Brackmann Scale 
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1 Normal
2 Mild dysfunction; slight weakness noticeable only on close inspection; may have slight synkinesis
3 Moderate dysfunction; obvious but not disfiguring difference between the 2 sides; noticeable but
not severe synkinesis
4 Moderately severe dysfunction; obvious weakness or disfiguring asymmetry, or both
5 Only barely perceptible motion
6 No movement
Table 1.   House-Brackmann Scale  (Continued)
House 1983; House 1985
 
 
Facial grading system
Resting symmetry Symmetry of voluntary movement Synkinesis
Compared to normal side Degree of muscle excursion compared to
normal side
Degree of involuntary muscle contrac-
tion associated with each expression
Eye
  Normal = 0
  Narrow = 1
  Wide =1
  Eyelid surgery = 1
Cheek
  Normal = 0
  Absent = 2
  Less pronounced = 1
  More pronounced =1
Mouth
  Normal = 0
  Corner drooped =1
  Corner pulled up/out = 1
Standard expressions
Forehead wrinkle
Gentle eye closure
Open mouth smile
Snarl
Lip pucker
Score each out of 5, where 5 is normal and
1 is gross asymmetry/no movement
Standard expressions
Forehead wrinkle
Gentle eye closure
Open mouth smile
Snarl
Lip pucker
Score each facial movement listed un-
der standard expressions on a scale 0 to
3, where 0 is no asymmetry and 3 is se-
vere asymmetry
TOTAL   TOTAL TOTAL
Table 2.   Sunnybrook Scale 
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Resting
symmetry
score x 5
  Voluntary movement score
Total x 4
Synkinesis score
Voluntary movement score - resting symmetry score - synkinesis score = composite Score
Table 2.   Sunnybrook Scale  (Continued)
Weighted regional evaluation using five separate expressions. Composite score from 0 (total paralysis) to 100 (normal function) (Ross 1996).
 
 
Mode Degree of paralysis
  4
normal
3
slight
2
moderate
1
severe
0
total
At rest          
Wrinkle forehead          
Blink          
Normal closure of eye          
Forced closure of eye          
Closure of eye on involved side          
Wrinkle nose          
Whistle          
Grin          
Depress lower lip/ blow out cheek          
Table 3.   Yanagihara Scale 
10 separate categories of function, each scored 0 (total paralysis) to 4 (normal), then summed, giving a total score from 0 (total paralysis)
to 40 (normal function) (Yanagihara 1977).
 
 
A P P E N D I C E S
Appendix 1. Cochrane Neuromuscular Specialised Register via the Cochrane Register of Studies (CRS-Web)
#1 MeSH DESCRIPTOR Facial Nerve Diseases AND INSEGMENT
#2 MeSH DESCRIPTOR Bell Palsy AND INSEGMENT
#3 MeSH DESCRIPTOR Facial Paralysis AND INSEGMENT
#4 MeSH DESCRIPTOR Hemifacial Spasm AND INSEGMENT
#5 (((bell* or facial* or hemifacial* or cranial*) NEAR3 (pals* or paralys* or paresi* or spasm*))) AND INSEGMENT
#6 #1 or #2 or #3 or #4 or #5 AND INSEGMENT
#7 MeSH DESCRIPTOR Acyclovir Explode 1 AND INSEGMENT
#8 MeSH DESCRIPTOR 2-Aminopurine AND INSEGMENT
#9 MeSH DESCRIPTOR Antiviral Agents Explode 1 AND INSEGMENT
#10 (aciclovir or valaciclovir or famciclovir or antiviral*) AND INSEGMENT
#11 (acyclovir or valacyclovir or famcyclovir) AND INSEGMENT
#12 #7 or #8 or #9 or #10 or #11 AND INSEGMENT
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#13 #6 and #12 AND INSEGMENT
#14 (#13) AND (INREGISTER)
Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies (CRS-
Web)
#1 MeSH DESCRIPTOR Facial Nerve Diseases AND CENTRAL:TARGET
#2 MeSH DESCRIPTOR Bell Palsy AND CENTRAL:TARGET
#3 MeSH DESCRIPTOR Facial Paralysis AND CENTRAL:TARGET
#4 MeSH DESCRIPTOR Hemifacial Spasm AND CENTRAL:TARGET
#5 (((bell* or facial* or hemifacial* or cranial*) NEAR3 (pals* or paralys* or paresi* or spasm*))) AND CENTRAL:TARGET
#6 #1 or #2 or #3 or #4 or #5 AND CENTRAL:TARGET
#7 MeSH DESCRIPTOR Acyclovir Explode 1 AND CENTRAL:TARGET
#8 MeSH DESCRIPTOR 2-Aminopurine AND CENTRAL:TARGET
#9 MeSH DESCRIPTOR Antiviral Agents Explode 1 AND CENTRAL:TARGET
#10 (aciclovir or valaciclovir or famciclovir or antiviral*) AND CENTRAL:TARGET
#11 (acyclovir or valacyclovir or famcyclovir) AND CENTRAL:TARGET
#12 #7 or #8 or #9 or #10 or #11 AND CENTRAL:TARGET
#13 #6 and #12 AND CENTRAL:TARGET
Appendix 3. MEDLINE (OvidSP) search strategy
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to July 30, 2019>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (486353)
2 controlled clinical trial.pt. (93185)
3 randomized.ab. (450604)
4 placebo.ab. (199708)
5 drug therapy.fs. (2127161)
6 randomly.ab. (315646)
7 trial.ab. (472150)
8 groups.ab. (1939321)
9 or/1-8 (4494102)
10 exp animals/ not humans.sh. (4603844)
11 9 not 10 (3889737)
12 exp Facial Nerve Diseases/ (16491)
13 bell palsy/ (1164)
14 facial paralysis/ or hemifacial spasm/ (12868)
15 ((Bell$ or facial$ or hemifacial$ or cranial$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).mp. (23603)
16 12 or 13 or 14 or 15 (36322)
17 Acyclovir/ (8662)
18 exp Acyclovir/ (13943)
19 2-Aminopurine/ (1348)
20 exp Antiviral Agents/ (343232)
21 (aciclovir or valaciclovir or famciclovir or antiviral$).tw. (82176)
22 (acyclovir or valacyclovir or famcyclovir).tw. (8204)
23 or/17-22 (382476)
24 11 and 16 and 23 (501)
25 remove duplicates from 24 (498)
Appendix 4. Embase (OvidSP) search strategy
Database: Embase Classic+Embase <1947 to 2019 July 29>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure.sh. (60421)
2 double-blind procedure.sh. (165969)
3 single-blind procedure.sh. (36041)
4 randomized controlled trial.sh. (564306)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1690153)
6 trial.ti. (284789)
7 or/1-6 (1875917)
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8 (animal/ or nonhuman/ or animal experiment/) and human/ (1923553)
9 animal/ or nonanimal/ or animal experiment/ (4308434)
10 9 not 8 (3597276)
11 7 not 10 (1722629)
12 limit 11 to (conference abstracts or embase) (1452930)
13 bell palsy/ (3925)
14 facial nerve paralysis/ or hemifacial spasm/ (26877)
15 ((Bell$ or facial$ or hemifacial$ or cranial$) adj3 (pals$ or paralys$ or paresi$ or spasm$)).mp. (41282)
16 or/13-15 (41282)
17 exp antivirus agent/ (944141)
18 aciclovir/ (37650)
19 famciclovir/ (3817)
20 (aciclovir or valaciclovir or famciclovir or antiviral$).tw. (113174)
21 (acyclovir or valacyclovir or famcyclovir).tw. (11679)
22 or/17-21 (977133)
23 12 and 16 and 22 (142)
24 remove duplicates from 23 (135)
Appendix 5. LILACS (IAHx) search strategy
("Bell palsy" or "paralisis de Bell" or "paralisia de Bell" or "facial or paralysis" or "paralisis facial" or "paralisia facial" or "hemi-
facial spasm" or "espasmo hemifacial") and (MH:D03.438.759.758.399.454.250$ or acyclovir or 2-Aminopurine or 2-Aminopurina or
MH:D27.505.954.122.388$ or aciclovir or acyclovir or valaciclovir or valacyclovir or famciclovir or famcyclovir or antivira$) and ((PT:"Ran-
domized Controlled Trial" or "Randomized Controlled trial" or "Ensayo Clínico Controlado Aleatorio" or "Ensaio Clínico Controlado
Aleatório" or PT:"Controlled Clinical Trial" or "Ensayo Clínico Controlado" or "Ensaio Clínico Controlado" or "Random allocation" or "Dis-
tribución Aleatoria" or "Distribuição Aleatória" or randon$ or Randomized or randomly or "double blind" or "duplo-cego" or "duplo-cego"
or "single blind" or "simples-cego" or "simples cego" or placebo$ or trial or groups) AND NOT (B01.050$ AND NOT (humans or humanos
or humanos)))
Appendix 6. ClinicalTrials.gov
("Bell palsy" or "facial palsy" or "facial paralysis")
Appendix 7. World Health Organization International Clinical TrialsRegistry Platform
("Bell palsy" or "facial palsy" or "facial paralysis")
W H A T ' S   N E W
 
Date Event Description
8 January 2019 New search has been performed The authorship had changed. Dhruvashree Somasundara,
Michael Sullivan and Fiona Gammie withdrew from this update.
We included four additional studies in the analyses (Minnerop
2008; Shahidullah 2011; Khajeh 2015; Khedr 2016). These sug-
gested that antivirals conferred additional benefit in the treat-
ment of Bell's palsy compared to the use of corticosteroids
alone. The new data were from small studies at high risk of bias.
19 March 2018 New citation required and conclusions
have changed
We performed sensitivity analyses that excluded studies at high
or unclear risk of bias in several domains, to analyse whether this
changed the results.
For our primary analysis we reported the meta-analysis exclud-
ing studies at high risk of bias. The risk ratio (RR) for incomplete
recovery was 0.81, 95% confidence interval (CI) 0.38 to 1.74; 3 tri-
als, N = 766, low-certainty evidence, in comparison to the pre-
vious version of the review, which reported a RR of 0.61, 95% CI
0.39 to 0.97; 10 trials, N = 1315; very low-certainty evidence.
We found no clear effect of antivirals combined with corticos-
teroids compared to corticosteroids alone in severe cases in this
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Date Event Description
update, based on our analysis of studies at lower risk of bias (RR
0.82, 95% CI 0.51 to 1.31; 2 trials, N = 98). The previous review re-
ported results from a larger data set and a RR of 0.64, 95% CI 0.41
to 0.99; N = 478.
For adverse events, when comparing antivirals plus corticos-
teroids to corticosteroids alone, we further downgraded the
body of evidence from the previous judgement of low, to very
low.
 
H I S T O R Y
Protocol first published: Issue 3, 1999
Review first published: Issue 2, 2001
 
Date Event Description
14 September 2015 Amended With the removal of Abdelghany 2013, this review concludes that
there is a benefit from the combination of antivirals with corti-
costeroids compared to corticosteroids alone for the treatment
of Bell's palsy of various degrees of severity. The evidence con-
tinues to support a benefit of combination therapy compared
with corticosteroids alone in severe Bell’s palsy. The evidence on
which these findings are based is of low quality.
14 September 2015 Amended Authors have removed a previously included study from the in-
cluded studies owing to withdrawal of the paper for plagiarism
(Abdelghany 2013).
22 May 2015 New citation required and conclusions
have changed
The authors have reviewed and reworded the conclusions, which
bear re-reading for clarification.
12 May 2015 Amended As an updated search was recently incorporated, there has been
no new search for this amended version.
28 February 2014 New citation required but conclusions
have not changed
Review updated with no change to conclusions. New authors:
Ildiko Gagyor, Vishnu B Madhok, Dhruvashree Somasundara,
Michael Sullivan, and Fiona Gammie. Previous authors Pauline
Lockhart, Marie Pitkethly, and Natalia Comerford withdrew.
22 January 2014 New search has been performed New trials added, text rewritten, new calculations, references up-
dated
12 May 2010 Amended Correction to reference
10 November 2009 Amended Correction of minor error in Discussion
25 February 2009 New citation required and conclusions
have changed
This is a substantive update to the previous edition of the review
with a new review team. Five new studies added to the analysis
with changes made to Results and Discussion sections as neces-
sary.
5 February 2009 New search has been performed Substantive update to previous edition of review.
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Date Event Description
Abstract and background information rewritten. Modification
of outcomes: all data from trials, whatever the trial length as
opposed to 6-month outcomes. Five new studies added to the
analysis with necessary changes made to Results and Discussion
sections. One study removed from the previous review as no da-
ta contributed and none forthcoming to previous authors when
approached.
1 November 2007 Amended Two trials, one with 551 participants comparing prednisolone
with aciclovir with both and with neither, another with 221 par-
ticipants comparing prednisolone and valaciclovir with pred-
nisolone and placebo have just been published and will be in-
cluded in an update of this review.
1 March 2004 New citation required and conclusions
have changed
Substantive amendment
1 January 2004 New search has been performed The review was updated in January 2004. Searches were up-
dated as follows: Neuromuscular Disease Group Trials Register
(searched April 2003), MEDLINE (searched January 1966 to April
2003), Embase (searched January 1980 to April 2003), and LILACS
(searched January 1982 to April 2003)
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All review authors contributed to the review and data extraction process. Professor I Gagyor wrote the first draS of the report with addi-
tional clinical input from Professor F Sullivan, Dr V Madhok, Dr F Daly. Professor I Gagyor incorporated the work into the existing review and
was responsible for the 'Risk of bias' and the GRADE assessment, data analysis, and use of Review Manager 5 and GRADEpro GDT software
(RevMan 2014; GRADEpro GDT 2015).
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
There were several differences between the published review protocol and the previous update of the review in 2015 (Gagyor 2015c). These
mainly reflected changes over time to treatment options and Cochrane methodology.
Antiviral treatment for Bell's palsy (idiopathic facial paralysis) (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
64
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• The search for studies included treatment with valaciclovir and famciclovir, either alone or in combination with any other therapy, to
reflect the treatment options now available for Bell's palsy.• We undertook 'Risk of bias' assessment according to Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Hig-
gins 2011).• We documented the selection criteria relating to high risk of bias and study duration. The minimum study duration was three months.• For this update, seven review authors read a selection of papers, reviewed them for 'Risk of bias', and extracted data. The review authors
distributed the work so that at least two review authors reviewed each paper. IG performed the final 'Risk of bias' assessment, which
FS and VM independently reviewed.• We focused the search on people who were immunocompetent, which we did not stipulate in the original protocol. We did this as
treatment protocols for immunocompromised individuals and treatment response may differ significantly from other individuals and
could not be fully explored in this analysis.• The authors of Lockhart 2009 widened the outcome criteria to include outcomes at the end of the study, as opposed to one year or six
months after treatment, in order to allow for the inclusion of a maximal number of published studies. This previous update included
studies with durations of three to 12 months, which allowed for maximum data inclusion. As it was understood that this method might
introduce significant heterogeneity to the results, the review authors included a sensitivity analysis looking at outcomes in participants
in studies reporting at 12 weeks or less and six months or less in order to assess the influence this had on the robustness of published
results. The authors of the current review accepted these changes. For the subgroup analysis of incomplete recovery, we extracted data
on the severity of Bell's palsy at month six or imputed using the last measure carried forward. As for the previous update, we omitted
the outcome 'complete facial paralysis at the end of the study'.• We have added in this update the outcome 'incomplete recovery in severe cases', measured at month six or imputed using the last
measure carried forward. We defined severe cases as a severe-to-complete facial paralysis, graded as equal to or greater than V in the
House-Brackmann grading system (House 1985), equal to or less than 20 in the Sunnybrook score (Ross 1996), and equal to or less than
20 in the Yanagihara score (Yanagihara 2003).• We modified the outcome measures since the previous review to take into account the heterogeneity of this group of studies.• We altered incomplete recovery to include the range of definitions used by the included studies in order to allow for maximum data
capture: as opposed to the previous definition of moderate dysfunction, the term now includes participants with a lack of full function.
By this definition, more participants will be classified as having 'incomplete recovery'.• The Lockhart 2009 update replaced 'adverse events attributable to antiviral treatment' with 'adverse events'; in studies where both
agents are administered, it is difficult to assess which agent is causing the adverse event. Similarly, even when only an antiviral is being
prescribed, it is difficult to know whether a specific event should be attributed to the medication or to another intercurrent cause. The
level of detailed analysis of adverse events in studies did not permit such a judgement to be made. This review reported adverse events
for each analysis separately.• The review authors added a 'Summary of findings' table and additional sections to the methods to comply with current Cochrane
standards.
For this update, three review authors read a selection of papers, reviewed them for 'Risk of bias', and extracted data. The review authors
distributed the work so that at least two review authors reviewed each paper. IG performed the final 'Risk of bias' assessment and assessed
the certainty of evidence using GRADEpro GDT 2015, which FS and VM independently reviewed.
We decided to include the data of the study of Lee 2013 in the main analysis, although Lee included participants with severe Bell's palsy
only. Since the proportion of participants with severe Bell's palsy in the remaining 13 studies was different, the heterogeneity between
the studies was high.
We conducted a subgroup analysis to assess heterogeneity between the studies. We analysed the effect of different antivirals (aciclovir,
valaciclovir and famciclovir) on the effect estimates for incomplete recovery (Analysis 2.1). An additional analysis shows the results of the
subgroup of patients with severe Bell's palsy (Analysis 2.2).
We performed sensitivity analyses for each outcome where possible, separately to investigate whether the exclusion of trials at a high or
unclear risk of bias in at least five categories influenced the results.
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